United States



LMG Life Sciences review

Financial & Corporate
Arnold & Porter

Arnold & Porter maintains a strong financial and corporate life sciences practice, with a team of reputable attorneys assisting a variety of clients in corporate counseling, licensing and collaborations, mergers, and other transactions.

Covington & Burling

Covington & Burling is a full-service firm with a strong presence in the life sciences space. The firm advises a number of companies in the industry in all aspects of financial legal matters, including corporate and venture capital offerings, transactions, and licensing agreements. A peer says the firm is “very strong” in the financial life sciences space with a “top tier’ group of attorneys.

Based in Washington DC, Catharine Dargan is a highly regarded life sciences practitioner and focuses her practice on advising both public and private companies in a variety of strategic transactions. Dargan was named this year’s LMG Life Sciences M&A Attorney of the Year.

Also located in the firm’s DC offices is Edward Britton, who focuses his practice on advising clients in a wide range of transactions, including joint ventures, licensing, and collaboration agreements. Van Ellis represents a number of biopharmaceutical, medical device, diagnostics, and consumer care companies.

John Hurvitz is co-chair of the firm's life sciences industry group, as well as head of the technology transactions group. A peer calls him an "excellent practitioner with broad experience."

Life sciences group vice chair Emily Leonard is based in Redwood Shores and has particular expertise in the licensing and collaboration space.

Dechert

Dechert is a full-service firm that is especially notable in the life sciences space for assisting clients in corporate transactions, licensing agreements and collaborations. One peer notes the firm is "top-tier" with an international presence, regularly representing clients in cross-border transactions.

David Rosenthal serves as co-leader of the life sciences practice and co-chair of the global corporate finance and capital markets practice. He represents clients in M&A and general corporate transactions, including recently leading a Dechert team that advised Zyla Life Sciences in its merger agreement with Assertio Therapeutics. In addition, Rosenthal also represented Diffusion Pharmaceuticals in two separate direct offerings.

Fenwick & West

Headquartered in Silicon Valley, Fenwick & West is a highly regarded law firm representing both large and emerging life sciences companies. The firm has a host of star practitioners that assist clients in corporate transactions, licensing and collaboration agreements, as well as venture financing.

Included among the firm’s stars is Effie Toshav, who focuses her practice on advising life sciences companies in all aspects of corporate transactions and governance. In particular, Toshav represents a number of innovative clients with initial public offerings (IPO) as well as mergers and acquisitions. Among her recent matters, Toshav recently assisted Passage Bio in its $248.4 million IPO as well as its subsequent collaboration with the University of Pennsylvania. One peer notes Toshav, who is this year’s LMG Life Sciences Corporate Attorney of the year, is “critical” and “the driving force behind [the firm’s] life sciences practice.”

Working closely with Toshav on a number of matters, including the Passage Bio IPO, are Stefano Quintini and Matthew Rossiter, both new additions to this year’s stars list. Quintini, who co-leads the firm’s digital healthcare practice and is noted by one peer as “fantastic” to work with, focuses on structuring and negotiating deals for a variety of life sciences clients. Rossiter is co-lead of the firm’s life sciences industry group and assists early-stage companies in a variety of corporate finance and governance matters.

Perennial star Robert Freedman also worked with Toshav, Quintini, and Rossiter on the Passage Bio IPO and serves as the firm’s capital markets and public companies practice group.

Gibson Dunn & Crutcher

Internationally known for its financial and corporate practice, full-service firm Gibson Dunn & Crutcher offers life sciences companies deep expertise handling complex transactions. The firm is particularly renowned for its corporate and M&A practices.

Financial and corporate star Ryan Murr is co-chair of the firm's life sciences practice group. One peer notes Murr is "very well respected" in the space and is "strong in capital markets and early stage capital" matters. In addition to transactions and financing, Murr also assists clients with licensing and collaboration agreements. In the past year, Murr represented Ultragenyx in its $320 million sale of future royalties of its Crysvita® product to Royalty Pharma. In addition, Murr advised several life sciences companies with their IPO’s, including Heron Therapeutics and Odonate Therapeutics.

Another star at the firm is Joseph Barbeau, who is widely recognized in the M&A space. Operating from both the firm's Beijing and Palo Alto offices, Barbeau handles a number of domestic and international life science transactions.

Karen Spindler is a perennial LMG Life Sciences star who recently joined Gibson Dunn from Goodwin Procter, strengthening the firm’s licensing and collaboration abilities.

Goodwin Procter

Goodwin Procter is a premier global law firm with a robust financial and corporate team focused on the life sciences industry. The firm, which was awarded this year’s LMG Life Sciences Corporate Firm of the Year, offers a deep bench of attorneys capable of assisting with public offerings, transactions, licensing, collaborations and venture-backed financing. "They have one of the largest and most successful corporate IP life sciences practices in Boston and the US," a peer says.

Kingsley Taft co-chairs the firm's life sciences group and is highly regarded in the field. One peer labels him the "dean” of Goodwin’s life sciences practice. Taft, who also holds a PhD in chemistry, regularly advises life sciences clients in a variety of business and financial affairs. Among his recent matters, Taft led the Goodwin team that represented Alnylam Pharmaceuticals in its $2 billion collaboration agreement with Blackstone. In addition, Taft advised Semma Therapeutics in its $950 million acquisition by Vertex Pharmaceuticals.

Serving alongside Taft as co-chair of the life sciences group is Mitchell Bloom, who "has a great knowledge base and is great to work with," a peer says. Bloom is particularly noteworthy for venture capital work, with one peer stating he is "probably the best VC lawyer" in the industry. Stuart Cable focuses on transactions and corporate financing, representing several high-profile clients. In the past year, Cable served as lead counsel for Moderna in two follow-on offerings which totaled more than $1.8 billion. Furthermore, Cable represented Spark therapeutics in its $4.4 billion acquisition by Roche.

Maggie Wong advises a variety of innovative public and private life sciences clients in raising capital. Wong recently led a Goodwin team representing BridgeBio Pharma with its $348.5 million initial public offering.

Gunderson Dettmer

Gunderson Dettmer is a highly reputable law firm with a strong reputation for assisting both emerging life sciences companies and funds in the venture capital space. In addition, their group of experienced practitioners advise a number of clients on licensing and collaboration agreements.

Timothy Ehrlich co-chairs the firm’s life sciences practice group representing both startups and established public life sciences companies throughout the entire corporate life cycle.  In particular, Ehrlich has developed a niche for assisting emerging clients with venture capital financing, most recently advising Affinivax, a vaccine development company, and Akous, a gene therapy firm, in separate Series B rounds. Furthermore, Ehrlich served as lead counsel for Lyndra Therapeutics in its collaboration with Gilead Sciences to develop HIV therapies.

Based in the firm’s Ann Arbor offices but also operating from Silicon Valley, Marcia Hatch is a new addition to this year’s stars list. Hatch represents emerging life sciences clients as well as underwriters in a number of deals. Among her recent matters, Hatch represented Comet Therapeutics in its Series A financing as well as PACT Pharma with its Series C funding.

Hogan Lovells

With several offices throughout the US and around the globe, Hogan Lovells maintains a strong international presence in the life sciences industry. The firm advises clients in the sector on all matters related to financing, licensing, and transactions. A peer praises the firm for its "excellent, deep knowledge of the life sciences industry."

Adam Golden is head of the corporate group in New York, and represents clients in several high-profile transactions as well as collaboration agreements. Golden, who one peer describes as “very strong in the space,” recently advised Novartis in its strategic collaboration agreements with IFM Therapeutics.  

Philadelphia-based Steve Abrams assists a variety of life sciences companies with corporate financing, transactions, licensing agreements and collaborations. Among his recent matters, Abrams represented Optinose, a pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) specialists, with its public offering worth $39 million.

Latham & Watkins

Latham & Watkins is a globally recognized, full-service firm with a robust life sciences group. The firm provides the full gamut of financial and corporate services for life sciences companies, and is noted for having an "excellent market share" of the biotech space, according to one peer. Clients of the firm range from startups to large public companies.

Judith Hasko is vice chair of Latham's life sciences and healthcare group, and is widely recognized for her work in the licensing and collaboration space. In the past year, Hasko represented Oasmia Pharmaceuticals in its strategic partnership with Elevar Therapeutics in a deal valued at nearly $700 million. In addition, Hasko also advised Ridgeback Biotherapeutics in its collaboration with Merck.

Charles Ruck focuses on life sciences transactions, serving clients from both the firm's Orange County and New York offices. One peer notes he is “smart, thoughtful and constructive.” Among his recent matters, Ruck was part of the Latham team that represented Amgen in its $2.7 billion acquisition of a 20.5% stake in China-based biopharmaceutical company BeiGene.

Co-chair of the firm’s life sciences and healthcare group is Brian Cuneo, who one peer notes has a “fantastic” reputation in the industry. In addition to his activity in capital markets, Cuneo is known for his work in the venture capital space, advising both venture funds and underwriters.  In the past year, Cuneo assisted Omniome in a Series C financing as well as AI-driven biopharmaceutical company Insitro with its $143 million Series B financing round. In recognition of his activity in the space, Cuneo was named this year’s LMG Life Sciences Venture Capital Attorney of the Year. 

Morgan Lewis & Bockius

Headquartered in Philadelphia with an additional thirty offices across the globe, Morgan Lewis & Bockius is a full-service firm with an established life sciences practice serving a variety of clients, from startups to market-leading companies. In addition to providing counseling on corporate financing, transactions, and venture capital matters, the firm has developed a particular focus on the licensing and collaborations space.

Benjamin Pensak represents a number of companies in the life sciences industry in all aspects of financial and corporate matters. He recently advised Eli Lilly in its collaboration with Evox Therapeutics to develop treatments for neurological disorders. In addition, Pensak led a Morgan Lewis team that represented Innovent Biologics in its $2.1 billion collaboration with Roche.

Working alongside Pensak is Alan Leeds, who co-chairs the firm's global life science practice and is the LMG Life Sciences Licensing & Collaborations Attorney of the Year. One peer notes Leeds is “very good, thoughtful, reasonable, and helps clients in a practical way.” In the past year, Leeds was part of a team representing Regeneron in a collaboration with Vyriad, which develops targeted cancer therapies. Leeds also led a team that advised Celgene in its collaboration agreement with Editas Medicine.

David Glazer is “fantastic” notes one peer and worked with Leeds on the Regeneron-Vyriad partnership. Glazer’s practice spans M&A, corporate transactions and licensing agreements. Among his recent matters, Glazer served as lead counsel to CRISPR Therapeutics in its licensing agreement with KSQ Therapeutics.

Mark Stein and Steven Navarro are recognized for representing both investors and companies in a variety of matters, including corporate financing, public offerings, transactions, and venture funding.

Ropes & Gray

Ropes & Gray has an established reputation in the life sciences industry for its strength in financial and corporate matters, and is recognized as this year’s Licensing and Collaboration Firm of the Year. In the M&A space, a peer calls Ropes & Gray a "high quality firm with excellent technical expertise." In addition to advising some of the largest companies in the industry, the firm also has represented a number of innovative startups.

David McIntosh is head of the firm’s IP transactions group and represents numerous companies in the life sciences industry, particularly in licensing agreements and collaborations. Among his recent clients, McIntosh served as lead partner representing Sarepta Therapeutics in licensing agreements with several entities, including Roche.

Working alongside McIntosh in Boston, Marc Rubenstein advises clients in a number of matters including public offerings, transactions, and licensing agreements. In the past year, he advised Allergan in its divesture of a clinical-stage gastrointestinal drug to AstraZeneca.

Christopher Comeau represents companies in mergers and acquisitions, and is highlighted by a peer for being a "terrific M&A lawyer with broad knowledge of the pharmaceutical industry." Comeau was active on the Sarepta licensing agreement with Roche.

Founder of the life sciences group and former chair Steven Wilcox is well regarded in the field for representing a variety of companies in complex deals, including corporate financings and mergers and acquisitions.

Sidley Austin

Sidley Austin is an internationally recognized firm with a strong reputation in financial and corporate matters for life sciences companies. The firm leverages its global team to assist clients with public offerings, transactions, licensing, collaborations, and venture capital financing.

Practicing out of the firm's Los Angeles and Palo Alto offices, Joshua Hofheimer has over 20 years of experience advising life sciences companies. Among his notable matters, Hofheimer represented Yuhan Corporation in its licensing and collaboration agreements with Gilead and Janssen, a division of Johnson & Johnson.

Based in Chicago, Pran Jha represents several clients in the life sciences industry with public offerings, transactions, and collaborations. Recent representations include CSL Behring and Vifor Pharma. In addition, Jha serves as co-chair of the firm’s diversity and inclusion committee.

Bay Area-based partners Jennifer Fitchen and Sharon Flanagan add to the firm’s West Coast credentials. Fitchen is global co-leader of the firm's mergers and acquisitions practice, and has extensive experience advising a number of life sciences companies in complex deals. Flanagan serves as managing partner of the firm's San Francisco office, and has over two decades of expertise in corporate governance, transactions, and securities offerings for clients in the industry.

WilmerHale

Dual-headquartered in Boston and Washington DC, WilmerHale offers life sciences companies a full range of corporate and finance-related legal services. One peer notes the firm has "excellent lawyers" in the space while another peer highlights their "great reputation" in Boston.

Steven Barrett is co-chair of the firm's technology transactions and licensing practice group. Recently, Barrett represented Ribometrix in a collaboration with Vertex Pharmaceuticals, and Medtronic in funding agreements with Blackstone Life Sciences.

Life sciences group co-chair Stuart Falber advises a variety of life sciences clients ranging from startups to established companies in the space. He specializes in corporate and venture capital transactions, as well as licensing and collaboration agreements. Among his notable matters, Fabler advised Epizyme in its $270 million collaboration agreement with Royalty Pharma.

Operating from both the firm's Boston and New York offices, Steven Singer has over 30 years of experience assisting both public and private life sciences companies in various transactions. Among his recent clients, Singer represented Fulcrum Therapeutics in its $72 million IPO.  

Lia Der Marderosian is chair of the firm's transactional department and advises life sciences clients in a variety of corporate matters, including offerings, transactions, and governance. Among her recent matters, Der Marderosian represented Pandion Theraupetics, a biotechnology company focused on autoimmune diseases, in its $80 million Series B financing.

A new addition to this year’s list is Cynthia Mazareas, who represents both a number of high-profile private and public life sciences companies with a variety of issued related to corporate governance and transactions. In the last year, Mazareas served as lead lawyer for Schrödinger in its $232 million IPO as well as Imara’s IPO, valued at $86.5 million.

Wilson Sonsini Goodrich & Rosati

A Silicon Valley institution, Wilson Sonsini Goodrich & Rosati is highly regarded for its robust financial and corporate practice focused on emerging life sciences companies. The firm assists clients in a number of matters involving transactions, licensing, collaboration, and venture capital.

Ian Edvalson advises a number of public and private life sciences companies on licensing agreements and strategic collaborative transactions. Among his recent clients, Edvalson represented CG Oncology in its collaboration agreement with Kissei Pharmaceutical for its oncolytic immunotherapy drug. In addition, Edvalson advised Mammoth Pharmaceuticals in a collaboration deal with GlaxoSmithKline to accelerate CRISPR-based Covid-19 diagnostics test.

Kenneth Clark is well known in the industry and has significant experience assisting clients with licensing agreements and collaborations, among other areas. Recently, Clark advised ORIC Pharmaceuticals in its $138 million IPO as well as IGM Biosciences with its offering which totaled $201.3 million.

Robert Ishii is based in San Francisco and primarily focuses on mergers and acquisitions in the life sciences space. Ishii was recently part of a Wilson Sonsini team that advised Forte Biosciences in its merger agreement with Tocagen, a biopharmaceutical company focused on gene therapy.

Financial & Corporate
Cooley

Cooley is considered a go-to firm for many life science companies because of its robust financial and corporate practice. The firm has over 90 attorneys nationwide involved in a variety of life science deals, transactions, and collaborations. Several peers have lauded the firm for being "top tier" with a group of “very good lawyers.”

Barbara Borden serves as co-chair of the firm's M&A practice, representing both targets and acquirers. Among her recent clients, Borden served as lead counsel advising Synthorx in its $2.5 billion sale to Sanofi.

Another star is Charlie Kim, who co-chairs the firm’s capital markets practice group and is regularly involved in some of the largest public offerings in the life sciences industry. In the past year, Kim was part of a Cooley team that represented underwriters JP Morgan in 10X Genomics’ $448.5 million IPO. Div Gupta is also highly regarded in the industry for representing several emerging companies as well as underwriters in private and public offerings. Gupta recently represented underwriter JP Morgan Chase in biotechnology company argenX’s $556 million and subsequent $862.5 million equity offerings.

In venture capital, Mark Weeks led a team counseling Procept BioRobotics on its $118 million equity financing round.

This year, recently retired partner and life sciences transactions veteran Barbara Kosacz was inducted into the LMG Life Sciences Hall of Fame for a standout career in this area.

Intellectual Property
Arnold & Porter

Arnold & Porter offers an IP group with strong practices in general patent litigation, Hatch-Waxman disputes and patent strategy for clients across technology areas. Major IP clients of the firm include Boston Scientific, Hologic, Sanofi and Bayer. For the group activity in high-profile, novel cases, Arnold & Porter was named 2020 General Patent Litigation Firm of the Year by LMG Life Sciences.

Bookoff McAndrews

DC-based Bookoff McAndrews is a standout for patent prosecution in the medical device and biotechnology sectors. The patent-focused boutique is active for life sciences clients with international footprints, as well as smaller emerging companies. A recent client says members of the team are “always reliable and provide outstanding services,” adding “their knowledge of our technologies and relationship with inventors is indispensable.”

Choate Hall & Stewart

Boston firm Choate Hall & Stewart is well known for its expertise in patent prosecution and strategy for life sciences clients, earning top ranking in these areas. The firm also has a significant practice focused on pharmaceutical patent litigation.

 

Life sciences co-chair Brenda Jarrell is a leader at the firm with a national reputation as a patent strategist. She was shortlisted by LMG Life Sciences for the Massachusetts Patent Strategy & Management Attorney of the Year award in 2020. IP co-chair Charles Lyon and Rolando Medina also focus their practices on patent counseling and strategy in the life sciences sector. Lyon currently serves as co-chair of the firm’s IP practice.

In the litigation group, co-chair Eric Marandett continues to be active for a number of clients in patent disputes. He is well regarded nationally for his expertise in high-profile IP litigation. In 2020, he was shortlisted for the General Patent Litigator of the Year award in New England.

Cooley

Cooley earns top ranking in prosecution and strategy for its deep bench of life sciences practitioners focused on the pharmaceutical, medical device and biotechnology areas. The firm also earned a national ranking for general patent litigation this year due to its significant activity in high-stakes disputes across product areas, including biologics. “Cooley did an excellent job managing the very large matter, which initially included over 30 patents,” a recent patent litigation client says. “They kept the in-house team well-informed and were a great partner.”

Global patent counseling and prosecution chair Ivor Elrifi was shortlisted for the Patent Strategy & Management Attorney of the Year award for New York, in part due to his status as one of the leading attorneys for prosecution and deal-oriented patent work. He currently advises Flexion Therapeutics on strategic patent portfolio management related to multiple products.

Mika Reiner Mayer is another standout in the patent practice, and was last year’s Patent Strategy Attorney of the Year for California. Mayer's practice involves prosecution and portfolio management for clients in the medical device and pharmaceutical industries. She currently assists Demetrix with patent prosecution, counseling and strategy work. Seattle's William Christiansen assists companies in the pharmaceutical, biotech, clean energy and medical device spaces.

For litigation, Michelle Rhyu is one of the firm's notable practitioners for her involvement in biologics disputes. “Michelle is an incredibly talented, very creative attorney who works extremely hard to achieve results for her client,” a recent client says. “She uses her excellent communication skills to effectively manage her team of skilled attorneys while keeping the client in the loop.”  Rhyu is currently acting for Amgen in a high-profile BPCIA litigation against Genentech. She was shortlisted for General Patent Litigator of the Year in California by LMG Life Sciences.

Covington & Burling

DC-based firm Covington & Burling offers deep expertise in general patent litigation and Hatch-Waxman disputes. The firm is highly ranked for its strength handling Hatch-Waxman cases for branded drug companies.

George Pappas is a leading litigator in the life sciences sector, with deep experience in ANDA litigations. Notable representations include AstraZeneca, Bristol-Myers Squibb and Merck. Christopher Sipes also stands out as one of the firm’s go-to practitioners for high-stakes life sciences disputes, offering experience in patent-related trials and appeals. Partner Jeffrey Elikan’s past representations in the pharmaceutical area include Invidior, UCB and Warner Chilcott against generic challenges.

Cravath Swaine & Moore

Longstanding firm Cravath Swaine & Moore is a staple amongst New York practices, and in IP offers a noteworthy group of attorneys handling life sciences patent litigation. The firm's technology area coverage includes matters related to pharmaceuticals, biotechnology and biologics. Representative clients include Abiomed, Amgen and DRIT Capital.

Firm chairman Evan Chesler is a leader across litigation areas, not least in IP, where he has made his mark in high-profile patent trials. Alongside Chesler in the firm's New York base is Keith Hummel, who has extensive experience in patent litigation for life sciences clients. Hummel and partner David Greenwald recently took part in the news-making antibody case Amgen v Sanofi, which resulted in a jury verdict in favor of client Amgen after the February retrial. Hummel is also active for Abiomed in a patent infringement dispute against Maquet Cardiovascular related to blood pump patents. Hummel was shortlisted for the New York Patent Litigator of the Year award by LMG Life Sciences.

Dechert

Dechert's life sciences team includes a large group of professionals focused on all areas of intellectual property. The firm is nationally ranked for its expertise in Hatch-Waxman disputes for branded companies and patent strategy.

Andrea Reid co-chairs the firm's global life sciences group and is an expert in strategic patent counseling and portfolio management. She recently assisted Arrakis Therapeutics with patent strategy and diligence for its $190 million collaboration with Roche to develop RNA-targeted drugs. Reid was the 2020 winner of the Patent Strategy Attorney of the Year award in Massachusetts.

In litigation, practice group leader Martin Black is deemed a "very fine lawyer" by a peer, and is noted for being a steadfast trial presence in the Hatch-Waxman arena. He recently represented Norgine in a generic challenge to its Plenvu product. Silicon Valley-based Jonathan "DJ" Loeb obtained a complete defense verdict for Quest diagnostics in a case involving patent infringement and trade secret claims. Robert Rhoad bolsters the firm’s life sciences patent litigation bench out of the Princeton office.

Kassie Helm is a new addition to the firm’s roster of stars, who gained previous recognition as the 2019 winner of the Rising Star in IP award by LMG Life Sciences. She was recently active for Eli Lilly in a successful antibody dispute against Genentech.

Fenwick & West

Fenwick & West is nationally ranked in patent prosecution and strategy for its team of attorneys versed in medtech and biotechnology. The firm also has a noteworthy practice focused on Hatch-Waxman disputes and general patent litigation.

Daniel Becker focuses on patent prosecution and strategic counseling for clients in the pharmaceutical and biotechnology industries. He was active as IP counsel on several deals, including Dermira in its $1.1 billion acquisition by Eli Lilly, and Passage Bio’s $248 million IPO. For his activity in the patent area, Becker was shortlisted for the Patent Strategy Attorney of the Year award in 2020. Robert Hulse is a key member of the firm's digital health practice, marrying his expertise in software and technology with Fenwick's life sciences clientele.

In New York, Jeffrey Oelke is well-versed in Hatch-Waxman disputes for branded drug makers. He is a significant part of the firm's growing profile in life sciences patent litigation, evidenced by recent work representing Pfizer against generic challengers in district court and before the PTAB.

Life sciences group co-chair Melanie Mayer is a new addition to the LMG Life Sciences stars list. She is currently active in pre-litigation matters for various clients of the firm. Adam Gahtan recently petitioned for Athena Diagnostics requesting certification by the US Supreme Court to hear the noteworthy Athena v Mayo case.

Finnegan Henderson Farabow Garrett & Dunner

Finnegan Henderson Farabow Garrett & Dunner earns top ranking across all practice areas in life sciences IP, including general patent litigation, Hatch-Waxman, patent prosecution and strategy. The IP firm is particularly notable for its reputation as a leader in PTAB and Federal Circuit matters. The firm garnered significant awards attention in 2020 after winning Patent Strategy Firm of the Year and a Patent Impact Case of the Year honor for the group’s involvement in the precedent-setting appeal Kaken v Iancu.

In regards to the firm's prosecution group, a client says: "They are highly skilled at writing and prosecuting applications. They have a great number of attorneys at different levels, and can handle the most complex cases even in short time frames." Thomas Irving is a nationally renowned patent prosecutor and expert on the America Invents Act, supporting the firm’s strong reputation as a go-to practice for IP counseling. Leslie McDonell is managing partner of the Boston office and a highly regarded practitioner in the patent arena. McDonell continues to be active for Vertex Pharmaceuticals in connection with its global patent strategy, along with partner Jill MacAlpine, whose diverse practice spans prosecution, litigation and counseling. MacAlpine was shortlisted for the Patent Strategy Attorney of the Year award in 2020 for her work in the area.

The firm’s patent litigation practice continues to be a staple of the firm, bolstered in part by respected practitioner Charles Lipsey, who draws on more than 40 years of experience in IP. He is currently representing AstraZeneca in a dispute against Zydus involving the client's blockbuster Farxiga product. John Livingstone and Barbara Rudolph impressed as two of the lead partners on the award-winning Kaken matter, which resulted in a precedential decision from the Federal Circuit that overturned an earlier PTAB ruling on obviousness. Rudolph was shortlisted for the General Patent Litigator of the Year award in DC for her contribution to this case and other matters.

Scott Burwell is another standout in the litigation group, showcased through his recent work for Eli Lilly in district court and before the PTAB. William Raich handles patent litigation and prosecution, often in the large molecule area. He is currently active for AbbVie, assisting the client with patent licensing and strategy.

Fish & Richardson

Fish & Richardson is highly ranked across practice areas in life sciences IP, including general patent litigation, Hatch-Waxman, patent prosecution and strategy. The firm received significant awards attention from LMG Life Sciences in 2020, earning the title of IP Boutique Firm of the Year and was winner of a Patent Impact Case honor for its involvement in the noteworthy Idenix v Gilead appeal.

Juanita Brooks earns national acclaim for her practice focused on patent litigation, and is turned to by many of the firm's major clients for high-stakes disputes. Among her many recent representations, Brooks was active for GlaxoSmithKline in a pharmaceutical dispute against Teva appealing an adverse decision that removed a $235 million verdict for the client. Chad Shear and Jonathan Singer acted for Gilead in the award-winning appeal against Idenix, which resulted in a novel ruling related to enablement. Following the noteworthy decision from the Federal Circuit, the panel denied the opponent’s request for en banc review. The PTAB arena continues to be a strong suit of the firm under the leadership of Dorothy Whelan, who co-chairs the post-grant proceedings group. Whelan was recently active for a major pharmaceutical client in connection with IPR challenges.

In the non-contentious arena, Teresa Lavoie is one of the firm's practitioners focused on patent strategy and portfolio development, most notably for clients in the biotechnology space. Janis Fraser is another leading patent attorney with a focus on the life sciences sector. She has deep experience as a counselor to biotechnology and pharmaceutical companies, and is noted for her work related to biologics. Gwilym Attwell is well-versed in patent prosecution, strategy and post-grant proceedings. He is currently part of a Fish team representing Astellas and Gilead in connection with a Hatch-Waxman dispute.

Gibson Dunn & Crutcher

Gibson Dunn & Crutcher is ranked nationally for its strength in general patent litigation, supported by a group of seasoned trial lawyers with life sciences expertise. The firm is also notable for its Hatch-Waxman practice representing branded drug makers.

Jane Love is one of the firm's leading patent trial lawyers, and was shortlisted in 2020 for the Branded Hatch-Waxman Litigator of the Year award by LMG Life Sciences. She and New York partner Robert Trenchard recently acted for Novartis in a noteworthy district court matter involving the client’s $2 billion drug Gilenya. The team was successful in moving for preliminary injunction, and won a subsequent appeal.

Wayne Barsky is co-chair of the firm's IP practice group, whose current focus involves a patent infringement suit for Amgen against Coherus related to the client’s large molecule drug Amgevita. Life sciences group co-chair Tracey Davies represented Natera against Illumina in a Northern District of California suit involving prenatal testing patents. In other matters, Davies is acting for Sanofi in five Hatch-Waxman suits concerning its insulin products.

The firm recently hired Joshua Lerner from Durie Tangri. He is well-versed in life sciences patent litigation, and has in-house experience as former senior litigation counsel at a major life sciences company.

Goodwin Procter

Boston-based Goodwin Procter offers a full-service life sciences IP practice, supported by top national rankings in general patent litigation, Hatch-Waxman and patent strategy. A pharmaceutical client highlights the firm for its “high technical competence” and “excellent litigation and trial skills.” For significant growth in its patent prosecution group and a strong year in litigation, Goodwin Procter was awarded 2020 Firm of the Year in Intellectual Property by LMG Life Sciences.

IP litigation chair Daryl Wiesen is a standout for disputes related to pharmaceuticals and biotechnology, supported by a client who says: “He's one of the best trial attorneys I've seen in action.” Wiesen was recently active for Fresenius Kabi in a patent dispute opposite Sanofi related to the branded product Jevtana. Elaine Herrmann Blais, who heads the litigation department in the Boston office, is one of the firm's specialists in biopharmaceutical matters. She was recently active in a significant Federal Circuit appeal for Dr Reddy’s involving the branded sublingual product Suboxone. Blais was shortlisted by LMG Life Sciences for the Patent Litigator of the Year award in New England.

Elizabeth Holland was on the shortlist for the Hatch-Waxman Litigator of the Year award in the generic category. She is well-known for her experience in pharmaceutical litigation, often for major clients like Teva and Actavis. Recent representations include Regeneron in Patent Office proceedings, and Actavis in an ongoing pharma dispute against Cosmo Technologies and Valeant.

In the non-contentious space, Theresa Kavanaugh focuses her practice on patent prosecution and portfolio development for early stage companies. She recently assisted a biopharmaceutical company in a licensing agreement with a major life sciences company. Duncan Greenhalgh has a strong reputation as a patent advisor to life sciences companies and a "great depth of biotech knowledge," according to a peer. Michael Shuster supports the firm’s West Coast offering in patent matters, recently assisting Mission Bio and other emerging clients in patent prosecution and strategy.

Greenberg Traurig

Greenberg Traurig offers a full-service IP group focused on the life sciences industry, earning national ranking in all areas, including general patent litigation, Hatch-Waxman disputes, patent prosecution and strategy. The firm boasts a sprawling network of offices in key IP jurisdictions like Boston, New York, Washington DC and Chicago, to name a few.

The firm's life sciences practice is led by Boston partner and co-chair David Dykeman, who focuses on patent procurement and strategy for clients in the medical device space, among other areas. Melissa Hunter-Ensor is vice-chair of the patent prosecution group, who provides expert IP counseling to life sciences clients. Some of her notable work includes building patent portfolios for companies in the biotechnology sector.

Fang Xie is co-chair of the biotechnology and pharmaceutical practice, specializing in strategic counseling and portfolio development for the firm's life sciences clientele. Barry Schindler is co-chair of the patent prosecution group and one of the firm’s standout practitioners focused on life sciences.

Scott Bornstein is global co-chair of the firm's IP and patent litigation practice groups, labeled by a client as "enthusiastic and creative." He is active in the firm's Hatch-Waxman group, helming patent disputes for notable generic drug makers including Teva and B Braun. Richard Pettus is another first-chair patent litigator and asset to the firm's pharmaceutical practice. He has been involved in more than 75 patent litigations during his career. Allan Kassenoff brings more than 20 years of experience to his practice focused on patent litigation, with a particular emphasis on Hatch-Waxman disputes.

Irell & Manella

Irell & Manella is a California-based firm with a top national ranking for general patent litigation. Most notably, the firm is a significant player in patent disputes related to biologics, with an expanding book of clients in the area. A peer praises Irell's litigation team over its competitors, saying they have a "deeper understanding of the law, dig into the facts more and are better strategic thinkers." Another peer says there is "an overabundance of talent at this law firm."

Morgan Chu is one of the most celebrated patent litigators in the country, and remains a leader in the firm's practice. He currently serves as chair of the litigation group. He won the Patent Litigator of the Year award in 2020 for a significant streak of cases, including his Supreme Court debut in Peter v NantKwest, and the blockbuster battle for Juno against Kite. Jason Sheasby represents the firm's incoming generation of litigation talent and has quickly developed a name in the legal market for his work in patent disputes.

Jones Day

Jones Day's IP group is highly ranked for general patent litigation with additional marks for Hatch-Waxman disputes and patent prosecution. The firm is notable for its broad geographic footprint, including major life sciences hubs New York and San Diego.

Global IP co-chair Anthony Insogna focuses his practice on a mix of patent litigation and portfolio management. His past representations include Celgene, AbbVie, and Merck entity Idenix, the last of which involved the largest damages award ever in a patent infringement case. Litigator Calvin Griffith has handled patent suits spanning numerous technology areas, including life sciences cases for Merck, Johnson & Johnson and AbbVie. Greg Castanias was shortlisted for the IP Appellate Litigator of the Year award in 2020 by LMG Life Sciences.

Patent prosecution co-head Adriane Antler is one of the firm's leading strategists for IP portfolios. She has expertise in matters related to biotechnology, pharmaceuticals and bioinformatics. Notable representations include Biogen, Sloan-Kettering Cancer Center and Acorda therapeutics. She was shortlisted for the New York Patent Strategy Attorney of the Year award by LMG Life Sciences.

Kilpatrick Townsend & Stockton

Kilpatrick Townsend & Stockton is highly ranked for its capabilities in patent prosecution, most notably in the medical device space. The firm also offers expertise in general patent litigation.

Tina McKeon has a strong reputation among life sciences IP strategists for her work advising companies in the biotech and pharmaceutical sectors. She specializes in prosecution, portfolio management and post-grant proceedings, bolstered by a PhD in neuroscience.

Silicon Valley partner Nena Bains contributes to the firm's deep expertise in medical device technology, supported by her in-house background as vice president of IP for Boston Scientific. Her practice focuses on patent portfolio development and transaction-related strategy. Darin Gibby has a multidisciplinary practice, focused on general patent litigation, post-grant proceedings, opinions and prosecution. He is often active for medical device clients.

Kirkland & Ellis

Kirkland & Ellis is top-tier in general patent litigation with an experienced bench of attorneys acting for major life sciences companies. The firm is well known for representing branded companies in Hatch-Waxman disputes, with some activity on the generic side as well.

James F Hurst is considered a leading trial lawyer for IP matters, and continues to be active for the firm’s major life sciences clients. In 2020, he was named the Midwest Patent Litigator of the Year by LMG Life Sciences for his representations of Abbott in a Federal Circuit appeal, and AbbVie in its closely watched patent antitrust case. Leora Ben-Ami is a highly regarded patent litigator with deep experience representing branded clients in pharmaceutical disputes.

Patricia Carson is an asset to the firm's patent litigation group with a practice almost entirely focused on life sciences companies. Thomas Fleming has extensive trial experience for clients in the pharmaceutical and biotechnology sectors.

Knobbe Martens

IP firm Knobbe Martens earns national ranking across all areas in IP, including top-tier status in generic Hatch-Waxman litigation, patent prosecution and strategy. "Knobbe has done everything right for our firm," a client says. "This is a remarkable firm [with] spectacular work and people."

Co-chair of the Hatch-Waxman and life sciences groups William Zimmerman contributes to the firm's leading status as a destination for generic pharmaceutical representation. Trial lawyer Joseph Re has more than three decades of experience in law and has handled matters across technology areas, most notably in the medical device industry. He was recently active for Personal Genome Diagnostics in a closely watched dispute. Medical device litigation co-chair Christy Lea is experienced in jury trials, appeals and post-grant proceedings. Fellow co-chair John Sganga offers deep experience in device patent litigation, showcased by a recent, global matter for Edwards Lifesciences against Boston Scientific.

Gerard von Hoffmann is a go-to patent strategist for clients in the medical device industry. He recently assisted Millipede Inc in its $450 million acquisition by Boston Scientific. Salima Merani has deep expertise in patent strategy, often connected to complex transactions and corporate matters. Biotechnology group chair Michael Fuller specializes in strategic patent counseling and portfolio management. He was recently involved in the above matter for Illumina against Natera.

Latham & Watkins

Latham & Watkins's IP group is highly recommended in general patent litigation, offering a strong bench of life sciences-oriented litigators versed across technology areas, including biologics. The firm has strategically moved towards representing branded drug manufacturers, resulting in recommended status in this year’s branded Hatch-Waxman litigation ranking.

IP litigation co-chair Michael Morin receives acclaim from numerous peers in the space, supported by his continued work in high-profile matters related to biologics. He and partner David Frazier recently acted for client AbbVie and Pharmacyclics in two patent infringement suits against AstraZeneca related to its Imbruvica drug. The matters recently settled. Morin was also engaged in a matter for Abbott in a medical device dispute against Integrated Sensing System. For his notable litigation activity and strong endorsements from the market, Morin won the DC Patent Litigator of the Year award by LMG Life Sciences.

Maximilian Grant is a respected litigator who had a major part in the firm’s IP growth. He recently represented InfoBionic in two cases brought by competitor CardioNet. Kenneth Schuler and Daniel Brown acted for Par Pharmaceutical in a Hatch-Waxman dispute in the District of Delaware involving the client’s branded Adrenalin injectable. The court found Par’s patents valid and infringed by Hospira.

The firm recently hired patent litigator Adam Perlman, who is currently listed is an LMG Life Sciences Star and is deeply experienced in branded Hatch-Waxman disputes.

Leydig Voit & Mayer

Chicago-based IP firm Leydig Voit & Mayer receives national rankings for its expertise in life sciences patent prosecution and strategy. In addition to the firm's non-contentious practice, it is also notable for pharmaceutical and biotech litigation.

John Kilyk Jr is well-versed in both patent litigation and strategic counseling for clients almost exclusively in the life sciences industry. He is a previous winner of the Midwest Patent Strategy Attorney of the Year award and was shortlisted in the same category for 2020. Kilyk and a team from the firm serve as patent counsel to longstanding client National Institutes of Health in connection with its biotech and chemistry innovations.

Salim Hasan continues to advise corporations, research institutions and universities in life sciences patent matters. He brings more than 25 years of experience to his practice. Steven Sklar was recently active in multiple Hatch-Waxman disputes for clients seeking to market generic pharmaceutical products.

Marshall Gerstein & Borun

Chicago-based boutique Marshall Gerstein & Borun is highly recommended in patent prosecution and strategy for life sciences companies, supported by a deep bench of technically trained attorneys providing IP advice. The firm also has significant practices in life sciences patent litigation and IP transactions.

Managing partner Jeffrey Sharp has more than 30 years of experience in patent law with a focus on the biotechnology and chemistry sectors.IP transactions chair Pamela Cox recently advised Salk Institute for Biological Studies on patent portfolio licensing strategy related to gene therapy platform technology. This year Cox was shortlisted for the Midwest Patent Strategy & Management Attorney of the Year by LMG Life Sciences for an active year assisting clients in IP-focused deals. Patent prosecution chair Heather Kissling focuses her practice on advising clients in the biotechnology space. She specializes in patent acquisition and strategy, with additional contentious expertise in interference proceedings.

In litigation, partner Sandip Patel was involved in the closely watched CRISPR dispute Regents of the University of California v Broad Institute, representing Dr Emmanuelle Charpentier and CRISPR Therapeutics in a European Patent Office appeal. Patel was shortlisted for the Midwest Patent Litigator of the Year award by LMG Life Sciences. Kevin Flowers and John Labbé recently took part in a Federal Circuit appeal of the BPCIA case Amgen v Hospira on behalf of Amgen, and Onyx Therapeutics in a successful Hatch-Waxman trial against Cipla. Julianne Hartzell is chair of the firm’s medical device practice, and also took part in the Federal Circuit appeal for Amgen.

Mayer Brown

Mayer Brown is recommended nationally for general patent litigation and Hatch-Waxman disputes for branded drug makers. In addition to the firm's contentious practice, the firm is also notable for its work in patent strategy, exemplified by its activity as IP counsel on complex life sciences deals.

IP practice group co-chair Lisa Ferri is a standout practitioner at the firm, and was shortlisted for the New York Patent Litigator of the year award by LMG Life Sciences. Her matters from the past year include representing Sanofi against the Washington Research Foundation in a suit related to the client’s drug Elitek, and a case for Gilead against eleven generic challengers seeking to market versions of branded Lexiscan. Ferri was also active as patent counsel on several M&A and licensing matters.

New York-based Brian Nolan is well versed in patent litigation, counseling and due diligence. He was recently active for Alexion as IP counsel in its $1.4 billion acquisition of Portola Pharmaceuticals. In litigation, he is lead counsel for the same client in a patent dispute opposite Chugai. Joseph Mahoney contributes to the firm's strength in Hatch-Waxman and Patent Office disputes. His life sciences expertise is bolstered by a Doctor of Pharmacy degree.

Patent attorney Vera Nackovic specializes in strategic counseling for clients in the pharmaceutical, biologics and medical device areas, among others.

McNeill Baur

IP boutique McNeill Baur is a firm entirely focused on life sciences, and is ranked nationally for its expertise in patent prosecution. The practitioners are well-versed in the biotechnology area, and have big law experience from a major IP firm. McNeill Baur continues to grow with the addition of experienced of counsel attorneys holding technical degrees.

Founding partners Rebecca McNeill and Amelia Feulner Baur specialize in a number of legal services, including prosecution, IP strategy, and post-grant proceedings. Both founding partners continue to be active in patent prosecution and strategic counseling for several major life sciences clients.

Mary Henninger brings her previous experience as a litigator to her current practice focused on patent prosecution and strategy. She recently assisted a life sciences client in a licensing agreement.

Rebecca Scarr joins the firm’s roster of LMG Life Sciences stars this year, in part due to her significant experience as patent counselor to clients in the biotech and pharmaceutical areas. Her life sciences expertise is supported by a Phd in biology.

Morgan Lewis & Bockius

International firm Morgan Lewis & Bockius provides a full-service IP practice in life sciences, earning national rankings in general patent litigation, patent prosecution and strategy. The firm has been one to watch for its significant streak of lateral hires over the past two years, bolstering the firm's capabilities in the contentious and non-contentious patent arenas.

Michael Abernathy currently serves as co-head of the firm's IP litigation and life sciences groups. He was part of a Morgan Lewis team representing Praxair in one of 2020’s Impact Cases of the Year that found method of treatment claims invalid under Section 101 of the Patent Act. Abernathy was shortlisted for the Midwest Patent Litigator of the Year award for his role in the matter. Global IP head Eric Kraeutler has more than four decades of experience in law, and focuses his practice on patent litigation.

In prosecution and strategy, Jeffry Mann is one of the firm's leading practitioners for life sciences patent advice. He specializes in patent preparation and prosecution, IP portfolio monetization, due diligence and licensing. Boston-based Steven Frank focuses his practice on IP transactions, patent prosecution and strategic counseling. Stephen Altieri is versed in patent portfolio development for emerging clients in a number of areas, including biologics, diagnostics and immunotherapies.

Louis BeardellChristopher Betti and Gargi Talukder all bring significant expertise to the firm’s patent prosecution and strategy practice. Talukder, a partner in the San Francisco office, recently assisted client Xencor with patent applications related to its antibody and protein platforms.

Morrison & Foerster

Morrison & Foerster offers a full suite of patent services for life sciences companies, most notably in the area of patent strategy and Hatch-Waxman litigation. The firm is also active in general patent litigation, specifically in the area of biologics.

Catherine Polizzi is a renowned patent strategist with a deep concentration on counseling companies in the life sciences area. In addition to building patent portfolios for sophisticated clients, she is also active in due diligences and other transaction-related matters.

Michael Ward serves as global head of the firm's life sciences industry group, and also leads the patent practice group. He focuses on portfolio management and strategic drafting of patent applications for life sciences companies. San Diego partner James Mullen specializes in patent prosecution, due diligence, and post-grant-proceedings. He is the founder and leader of the firm's antibody patent group.

In the litigation department, Michael Jacobs is a leading first-chair trial lawyer with significant experience in life sciences patent disputes. He currently co-chairs the IP practice group. Deanne Maynard has handled some of the more significant life sciences IP appeals of late. She previously won the IP Appellate Litigator of the Year award from LMG Life Sciences, and was shortlisted in the same category this year.

New to the stars list is Janet Xiao, who focuses her practice on patent prosecution, portfolio management and counseling for clients across life sciences technology areas.

O'Melveny & Myers

O'Melveny & Myers is a recommended firm in the area of Hatch-Waxman litigation for branded pharmaceutical companies. The firm acts for a number of major entities, including AstraZeneca, Amgen subsidiary Onyx Therapeutics and ViiV Healthcare.

New York-based Lisa Pensabene is the 2020 Branded Hatch-Waxman Litigator of the Year for a significant year of trial work and repeated market praise. She recently led a trial team for Amgen subsidiary Onyx related to its Kyprolis drug. The District of Delaware ultimately found the client’s patents valid following novel challenges to compound and formulation claims covering its product. Pensabene currently serves as the firm’s life sciences IP litigation head.

John Kappos is another noteworthy litigator at the firm, bringing two decades of experience in law. He is currently acting for Agilent Technologies in a trade secrets suit brought against a competitor.

New to the stars list is Hassen Sayeed, who acted alongside Pensabene in the Onyx litigation. His technical credentials are bolstered by a medical degree.

Paul Weiss Rifkind Wharton & Garrison

Paul Weiss Rifkind Wharton & Garrison is highly ranked for its strength in general patent litigation, notably in biosimilars disputes and post-grant proceedings. "Their trial attorneys have a deep understanding of the technology at issue and are quick on their feet," a peer says. Paul Weiss has one of the pioneering practices in biosimilars litigation, a continuing area of focus for the firm.

The firm's position as a leading practice in the large molecule space is in part due to litigator Nicholas Groombridge, an IP trial lawyer with more than 25 years of experience. He also has deep experience in patent disputes related to pharmaceuticals and medical devices. Groombridge was shortlisted as the New York General Patent Litigator of the Year in 2020 by LMG Life Sciences.

DC-based partner Steven Baughman is a leading practitioner for post-grant proceedings. His past representations include IPRs for Nevro Corporation and Chugai Pharmaceutical. Eric Stone is another standout in the firm's roster of stars for his significant work in patent litigations involving large and small molecule products.

Perkins Coie

West Coast-based firm Perkins Coie is nationally ranked for its practices focused on generic Hatch-Waxman litigation and patent prosecution. The firm represents a diverse mix of clients in the life sciences sector, including companies in the pharmaceutical, biotechnology and medical device areas. For a significant streak represent generic companies in novel pharmaceutical litigations, Perkins Coie was awarded Hatch-Waxman Litigation Firm of the Year for Generics in 2020.

"Our view is the specific attorney makes all of the difference, and Michael Wise at Perkins Coie has consistently created value for our firm through his work," a client says about the firm's life sciences industry group chair. Wise specializes in patent prosecution, portfolio development and litigation in the life sciences sector. He recently assisted patent prosecution client Eloxx Pharmaceuticals in IP diligence related to its $30 million common stock offering. Wise also continues to represent City of Hope in connection with patent filing and prosecution. Seattle-based Paul Parker is chair of the firm's medical device industry group. He receives repeated praise from peers in the space for his work counseling companies on their med tech portfolios.

Shannon Bloodworth co-chairs the firm's IP practice group, and is one of the country's leading litigators for Hatch-Waxman disputes. She and Brandon White acted as lead in the newsworthy pharmaceutical dispute Biogen v Mylan. The firm’s client Mylan received a favorable trial outcome when a West Virginia judge found 13 claims covering Biogen’s blockbuster Tecfidera drug did not meet written description requirements under Section 112. Bloodworth was shortlisted for a Litigator of the Year award category and the firm won the Generic Hatch-Waxman honor in part due to this matter.

Quinn Emanuel Urquhart & Sullivan

Litigation boutique Quinn Emanuel Urquhart & Sullivan receives a top ranking for its specialization in patent disputes for clients in the pharmaceutical, biotechnology and medical device sectors. The firm is also notable for its capability in Hatch-Waxman matters for branded drug makers.

Life sciences global co-chair Peter Armenio is one of the firm's leading ANDA litigators, and has a national reputation as an IP trial lawyer. Notable representations include Forest Laboratories, Mallinckrodt and GlaxoSmithKline. Raymond Nimrod was awarded New York General Patent Litigator of the Year in 2019 by LMG Life Sciences for his notable work in the high-profile CRISPR dispute Regents of the University of California v Broad Institute.

Nick Cerrito leads the national life sciences practice, and is also noted for his ability as a trial-ready lawyer for branded pharmaceutical clients. Eric Stops focuses his practice on pharma patent disputes, with additional expertise in FDA counseling, portfolio management and opinions. Experienced patent litigator Colleen Tracy James adds to the firm's strong bench of trial lawyers active in the Hatch-Waxman space.

Rakoczy Molino Mazzochi Siwik

"Rakoczy Molino Mazzochi Siwik is the firm we go to for complex and challenging legal issues," a pharmaceutical client says about the patent litigation-focused IP boutique. "They provide comprehensive, well-thought-out and strategic advice on the most complex and challenging legal issues in the pharmaceutical industry." The firm, based in Chicago, receives top-tier ranking as a practice for Hatch-Waxman litigation, and was shortlisted for the Generic Firm of the Year award in 2020. The firm is best known for representing generic pharmaceutical clients, but is also becoming active in the biosimilar litigation arena.

William Rakoczy is recognized as a leading patent litigator in the life sciences industry, underscored by his honor this year as one of a few inductees into the LMG Life Sciences Hall of Fame. The recognition highlights his stellar career as a courtroom advocate for companies in the pharmaceutical area. Mr Rakoczy and LMG Life Sciences newcomer Eric Hunt were recently active for Mylan in a biosimilar litigation, the first matter under the BPCIA for the client.

Paul Molino is managing partner of the firm and another one of the group's experienced litigators. He and Mr Rakoczy are currently active for Apotex, Sandoz and Dr Reddy’s in connection with patent infringement claims brought by Astellas and Gilead. The consolidated matter is currently scheduled for trial in 2021.

Robins Kaplan

Minneapolis-based Robins Kaplan is nationally recommended for its IP group focused on generic Hatch-Waxman litigation. A client says the IP team is "thoughtful and methodical in its work on our behalf in a number of high-stakes litigation matters," and "repeatedly demonstrates that our interests are 'top of mind' for them."

Health and life sciences industry group chair Jake Holdreith is focused on pharmaceutical patent litigation for the firm's generic clientele. He is currently active for Collegium Pharmaceutical as lead counsel in a series of cases involving patents owned by Purdue. The case has been stayed due to Purdue’s recent bankruptcy declaration. In another matter, Holdreith is representing Amneal as trial counsel against Amgen related to the opponent’s branded Sensipar product. Ronald Schutz is a notable litigator at the firm, and currently serves as chair of the executive board.

New to the LMG Life Sciences Stars list are Jeffrey Hovden and Oren Langer, both experienced practitioners in the patent litigation arena. They are currently representing Torrent Pharmaceuticals in a Hatch-Waxman dispute against Bial-Portela and Sunovion.

Rothwell Figg Ernst & Manbeck

Based in DC, Rothwell Figg Ernst & Manbeck is an IP firm recommended nationally for its practice dedicated to Hatch-Waxman litigation. The firm is known for its representation of generic pharmaceutical clients, and in addition to this area is active in post-grant proceedings and patent prosecution. The firm has recently been involved in biologics matters.

Founding partner E Anthony Figg is one of the preeminent Hatch-Waxman specialists in the market, supported by a long career of representations in pharmaceutical patent disputes. He is currently active for Biogen in patent prosecution and portfolio management, and in the litigation arena is representing the client in post-grant proceedings related to its Avonex product. Figg is one of a few practitioners honored in the LMG Life Sciences Hall of Fame.

Joseph Hynds took part in a notable post-grant matter for client Coherus BioSciences, which resulted in denied institution of a PGR that sought to challenge its patent covering large molecule drug adalimumab. Steven Lieberman was active in multiple post-grant proceedings for Dentsply Sirona against Edge Endo. The PTAB denied institution of the four petitions brought by the opponent Edge Endo.

R Danny Huntington specializes in patent prosecution, licensing and litigation, with particular expertise in patent interferences. He currently assists Broad Institute licensee Editas Medicine with patent prosecution related to its CRISPR portfolio.

Sidley Austin

Sidley Austin's IP group has top-tier status in general patent litigation and Hatch-Waxman disputes for branded drug makers. In addition to the firm's expertise in small molecule pharmaceutical matters, the litigation team is also active in the biosimilars space. The firm received significant awards attention in 2020, winning multiple practitioner categories and a Patent Impact Case of the Year award for its involvement in the high-profile appeal Immunex v Sandoz.

One of the firm’s IP litigation heads is Jim Badke, whose practice focuses on life sciences-oriented patent disputes. He is currently active for Bayer Healthcare in a biologics litigation against Baxalta and Nektar involving the client’s Jivi product. In another matter, he is active for Amgen in a Hatch-Waxman litigation opposite multiple generic challengers to the company’s Sensipar drug. Ching-Lee Fukuda is the 2020 Post-Grant Proceedings Attorney of the Year for her significant activity in PTAB matters, including the recent appeal of an IPR for client Nevro invalidating a key Boston Scientific patent. She was also active in a Patent Impact Case of the Year CardioNet v InfoBionic, which reversed a ruling citing Section 101. Vernon Winters bolsters the firm’s strong West Coast offering for IP, often acting in high-stakes disputes for life sciences client across product areas.

In the appellate area, Supreme Court group founder Constantine Trela earned the title of 2020 Appellate Practitioner of the Year in IP for his involvement in the award-winning Immunex v Sandoz appeal, which dealt with obviousness-type double patenting.

Sterne Kessler Goldstein & Fox

DC-based firm Sterne Kessler Goldstein & Fox earns top rankings across multiple practice areas in IP, including Hatch-Waxman litigation, patent prosecution and strategy. The firm is also well-known as a destination shop for post-grant proceedings, an area of high activity for the group over the past year. Sterne Kessler earned significant awards attention from LMG Life Sciences in 2020, with recognition as Inter-Partes Review Firm of the Year and as lead firm in the Hatch-Waxman Impact Case of the Year Amneal v Almirall.

Eldora Ellison is renowned for her expertise in patent strategy and post-grant proceedings. “One of my all-time favorite people is Eldora Ellison,” a peer says naming recommended attorneys in the area, while another labels her “a very talented, excellent attorney.” Ellison is currently involved in the newsworthy CRISPR battle between the University of California and Broad Institute, which continues with the recent initiation of a patent interference by the Patent Office. She is also active for Bristol-Myers Squibb in patent portfolio management related to small and large molecule products.

Biotech partner and patent prosecution chair Eric Steffe specializes in prosecution, portfolio development and post-grant proceedings. Steffe is also on the team representing University of California in CRISPR-related matters. Deborah Sterling and Gaby Longsworth are currently active for Teva in the appeal of PTAB rulings connected to its patent antibody product Ajovy. LMG Life Sciences newcomer Carla Ji-Eun Kim is a well-versed practitioner focused on patent prosecution and strategy, who advises on Bristol-Myers Squibb’s portfolios alongside Ellison.

In litigation, John Christopher "JC" Rozendaal is co-chair of the firm's trial and appellate practice group. This year he was active for Teva in a significant patent trial for Teva that ultimately cleared patents covering Narcan for generic market entry. Dennies Varguhese is a standout in the firm’s Hatch-Waxman practice who recently drew attention as a lead in the noteworthy Patent Impact Case Amneal v Almirall, which was a precedent-setting appeal involving attorneys’ fees. Gaby Longsworth was also active in the matter.

Weil Gotshal & Manges

Weil Gotshal & Manges is nationally ranked for its expertise in general patent litigation. The firm's IP litigation team is active in several technology areas, including pharmaceuticals, biologics, diagnostics and the burgeoning genetic testing space.

Renowned IP lawyer Edward Reines is co-head of the firm's patent litigation practice and life sciences industry group. He has significant first-chair experience in patent disputes, and is particularly known for his effectiveness in appeals. Reines recently acted for Bio-Rad Laboratories and the University of Chicago in a litigation brought against 10X Genomics, resulting in a an upheld $24 million patent jury verdict in favor of the clients. Reines was shortlisted in 2020 for the General Patent Litigator of the Year award in California.

Patent litigation and life sciences group co-head Elizabeth Weiswasser is an acclaimed attorney for high-stakes IP trials. In one matter, she is representing Sanofi in IPR proceedings and district litigation related to its branded Lantus insulin products. Weiswasser is also active for Johnson & Johnson subsidiary Ethicon in a patent infringement suit before the ITC. For her work in the area, Weiswasser was shortlisted for the General Patent Litigator of Year award in New York.

Williams & Connolly

DC litigation boutique Williams & Connolly is highly ranked across litigation areas, including general patent litigation and Hatch-Waxman disputes. The firm frequently represents branded pharmaceutical makers and is one of the leading practices for biologics disputes. Williams & Connolly was shortlisted for the Branded Hatch-Waxman Firm of the Year award in 2020 for its activity in the area.

Patent litigation practice founder Bruce Genderson is one of the firm's acclaimed trial lawyers focused on Hatch-Waxman disputes. He is currently active for Bayer in a Hatch-Waxman litigation involving its cancer drug Stivarga, and for Merck in a separate matter involving challenges to its Januvia, Janumet and Janumet XR products. Genderson is a previous awardee of the Hatch-Waxman Litigator of the Year award, earning the title in 2019 for his work in the area.

In the large molecule space, partner David Berl is a go-to litigator for biologics cases. He and partner Paul Gaffney are currently active for Genentech against Amgen in a BPCIA litigation related to the client’s Avastin drug. The matter is one of the more closely watched large molecule disputes currently pending, and is scheduled for trial in late 2020. Thomas Selby was active alongside Berl in a Hatch-Waxman dispute for Pfizer entity Anacor Pharmaceuticals against ten generic challengers seeking to market versions of its Kerydin product. Jessamyn Berniker is representing AstraZeneca and Nektar Therapeutics in IPRs related to a generic challenge to the clients’ Movantik patent.

WilmerHale

WilmerHale's life sciences IP group is highly recommended for general patent litigation and Hatch-Waxman disputes for branded drug makers. The firm is also notable for its expertise in patent prosecution and post-grant proceedings. "I have worked with and against this firm and find their work to be top-notch," a peer says about the litigation practice.

William Lee is one of the most celebrated patent litigators in the country, offering more than four decades of experience in law. Although his practice spans industries outside of life sciences, he is often involved in key patent disputes facing the firm’s life sciences clients. IP litigation group co-chair Lisa Pirozzolo is an experienced first-chair trial lawyer who is representing several notable life sciences clients, including CSL Behring in a dispute against Biogen related to hemophilia treatment.

New York partner Robert Gunther is a key member of the firm’s life sciences patent litigation bench, and was honored in 2020 as the General Patent Litigator of the Year in New York for his significant activity in the area. Among his notable representations was a consolidated case for Roche and Becton Dickinson against Enzo Life Sciences, which resulted in a noteworthy Federal Circuit ruling involving enablement issues. The matter was named one of 2020’s Patent Impact Cases of the Year and Gunther in part won the Litigator of the Year award due to his involvement.

DC-based partner Amy Wigmore is currently active for Bristol-Myers Squibb and Pfizer in a Hatch-Waxman litigation opposite several generic manufacturers that at one point totaled 25 challengers. PTAB expert Emily Whelan was active alongside Wigmore in the matter, and is separately involved in a Hatch-Waxman dispute for Akebia and Keryx involving 14 patents related to its Auryxia drug.

Patent attorney Colleen Superko specializes in portfolio development, strategic counseling and licensing, among other areas. She currently assists H Lundbeck with several patent portfolios and related PTAB challenges.

Wilson Sonsini Goodrich & Rosati

Bay Area staple Wilson Sonsini Goodrich & Rosati is highly recommended in generic Hatch-Waxman litigation and patent strategy. The firm is also notable for its expertise in patent filing and prosecution.

Vern Norviel is a preeminent patent strategist for clients in the life sciences industry and leader of the firm's patents and innovations counseling practice group. He specializes in patent prosecution, strategy and portfolio development. Norviel recently assisted client 10x Genomics in patent matters related to its $50 million Series D financing.

San Francisco partner Michael Hostetler was named the 2020 Patent Strategy Attorney of the Year in California for his notable year of practice assisting clients with portfolio management and deal-oriented advice. Among his many recent representations, Hostetler was active for Crinetics Pharmaceuticals in patent matters related to a recent public offering, and Horizon Therapeutics as IP counsel in its acquisition of Curzion Pharmaceuticals. James Heslin is an expert in the medical device field, drawing on more than 20 years of experience as a patent counselor.

Winston & Strawn

Winston & Strawn's IP group is highly recommended in general patent and Hatch-Waxman litigation. The firm is most notable for being one of the most active generic practices in the Hatch-Waxman domain, and for its recent involvement acting for biosimilars clients in BPCIA disputes.

Litigation group co-chair George Lombardi is considered one of the foremost trial lawyers in the ANDA litigation area, a reputation bolstered by a significant year of patent work in the life sciences area. IP co-chair Charles Klein is another standout litigator in the firm's life sciences group, offering significant experience in Hatch-Waxman and biosimilars suits. Maureen Rurka is a respected litigator focused on disputes related to pharmaceuticals and biosimilars.

First-chair trial lawyer Michael Nutter focuses his practice full-time on life sciences matters. He acts as litigation counsel for the firm's many high-level generic clients, and is also involved in the growing area of BPCIA suits. Nimalka Wickramasekera was shortlisted by LMG Life Sciences for the Intellectual Property Rising Star award in 2019, and is one of the firm’s experienced attorneys in the area of Hatch-Waxman litigation.

Wolf Greenfield & Sacks

Boston-based IP boutique Wolf Greenfield & Sacks earns top ranking for its expertise in patent prosecution and strategy for life sciences clients. “Their level of service and expertise is not easily matched,” says a client, while another adds: “They are very responsive and have worked hard to give us excellent service – and we are not an easy client.” The firm is notable for its significant number of attorneys with advanced scientific degrees, showcased by its biotech group, which is made up of more than 80% PhD or MD holders. Wolf Greenfield also offers a substantial practice focused on post-grant proceedings.

Timothy Oyer is firm president and managing partner, focusing his personal practice on patent prosecution, counseling and matters related to transactions. Biotechnology group chair Helen Lockhart specializes in patent prosecution and portfolio development for a variety of clients, including universities and research institutions, startups and midsize companies. She is currently advising a biotech startup in patent portfolio strategy. Edward Gates, deemed a "brilliant attorney" by a peer, has extensive experience counseling clients in the pharmaceutical and biotechnology areas on licensing and patent matters. Gates acted for Epizyme in two IPRs seeking to challenge patents owned by GlaxoSmithKline. The IPRs were recently instituted by the PTAB.

Maryanne Trevisan provides clients with deep prosecution expertise in a number of advanced scientific areas, including cell biology and cancer therapies. Biotech partner Patrick RH Waller currently advises Oxford Nanopore in patent portfolio strategy and Prevail Therapeutics with respect to patent prosecution and IP diligence. Hunter Baker is chair of the pharmaceuticals practice group and a specialist in patent prosecution, strategic counseling and technology transactions. He was recently active for academic clients in life sciences technology licensing.

Intellectual Property
Venable

Venable receives top-tier status in branded Hatch-Waxman litigation and patent prosecution, with additional rankings in general patent litigation and strategy. A peer calls the firm "a force to be reckoned with in Hatch-Waxman."

IP group co-chair Dominick Conde is a leader in the firm's Hatch-Waxman litigation practice with more than 25 years of experience in law. He recently acted for Nalpropion in a Federal Circuit appeal against Actavis, resulting in a favorable ruling for the client. Scott Reed is co-chair of the firm's IP litigation practice group, specializing in pharmaceutical, biotechnology and medical device disputes. Ha Kung Wong specializes in patent and trade secret litigation, often for clients in the pharmaceutical area.

William Solander is a first-chair trial lawyer who recently represented Sanofi in a novel IPR appeal that vacated a decision made by the PTAB. John Murnane's career in patent litigation spans more than 30 years, during which time he has accumulated expertise in district court, ITC, Federal Circuit and post-grant matters. Christina Schwarz and Nicholas Kallas acted for Novartis in a second ANDA litigation against Lupin involving allegedly infringed patents covering Entresto.

For non-contentious work, Alicia Russo is one of the firm's expert patent strategists, advising clients in the biologics and pharmaceutical sectors.

Life Cycle
Arnold & Porter

Arnold & Porter maintains a substantial presence in the life sciences industry, with a practice that encompasses all legal areas needed to support a product's life cycle. The firm ranks highest in pricing and reimbursement and antitrust litigation, but is also a significant player in patent litigation, patent strategy, M&A and FDA counseling. The firm offers roughly 200 attorneys dedicated to the industry area, nearly half of whom hold scientific degrees.

Covington & Burling

Covington & Burling offers a broad-based practice in the life sciences space, with a deep bench of attorneys who contribute to the firm's longstanding reputation in regulatory counseling, transactions, patent litigation and white-collar matters. LMG Life Sciences currently recognizes 16 individuals from the firm as stars across the four main practice areas.

For regulatory work, one peer notes Covington is the "firm to beat" in the pharmaceutical space. Active in this group is Michael Labson, who was shortlisted by LMG Life Sciences for the top attorney award in the FDA Pharmaceutical area. Pamela Forrest has over 20 years of experience handling FDA matters for medical device clients. She advises clients throughout the entire life cycle including pre-market notification and approval, product recalls, and device labeling and promotion. In the pricing space, Geoffrey Hobart is active in FDA investigations involving issues related to the False Claims Act, Anti-Kickback Act and Medicaid Rebate statute violations.

In IP, Covington offers deep expertise in general patent litigation and Hatch-Waxman disputes. George Pappas is a leading litigator in the life sciences sector, with deep experience in ANDA litigations. Notable representations include AstraZeneca, Bristol-Myers Squibb and Merck. Christopher Sipes also stands out as one of the firm’s go-to practitioners for high-stakes life sciences disputes, offering experience in patent-related trials and appeals.

For financial and corporate matters, a peer says the firm "has a strong subject matter expertise and is pragmatic in their approach." Catharine Dargan is a highly regarded life sciences practitioner and focuses her practice on advising both public and private companies in a variety of strategic transactions. Dargan was named this year’s LMG Life Sciences M&A Attorney of the Year. Life sciences group vice chair Emily Leonard is based in Redwood Shores and has particular expertise in the licensing and collaboration space. John Hurvitz is co-chair of the firm's life sciences industry group, as well as head of the technology transactions group.

The firm receives top ranking in government investigations and white-collar matters, and is also notable for its antitrust and product liability groups. Ethan Posner stands out as one of the firm's leading litigators in the white-collar space. Michael Imbroscio co-chairs the product liability practice. In the past, he has litigated on behalf of major pharmaceutical clients in products suits, including Bayer, Boehringer Ingelheim and Eli Lilly.

Goodwin Procter

General practice firm Goodwin Procter offers a strong roster of attorneys servicing life sciences clients in all practice areas, but is most notable for being a powerhouse in IP and transactions. The firm receives top ranking in patent litigation, patent strategy, licensing, M&A, venture capital and general corporate work.

The firm was awarded Firm of the Year for Intellectual Property in 2020, due to its strong practices focused on patent litigation, prosecution and strategy. IP litigation chair Daryl Wiesen is a standout for disputes related to pharmaceuticals and biotechnology, and was recently active for Fresenius Kabi in a patent dispute opposite Sanofi related to the branded product Jevtana. Elaine Herrmann Blais took part in a significant Federal Circuit appeal for Dr Reddy’s involving the branded sublingual product Suboxone. She was awarded Patent Litigator of the Year in New England. For prosecution, Duncan GreenhalghTheresa Kavanuagh and Michael Shuster provide strategic portfolio advice to companies in novel technology areas.

In the financial area, Goodwin Procter was named 2020 Corporate Firm of the Year. The firm assisted several clients with their public offerings, including Argenx in a global offering valued at $862.5 million, and BridgeBio in the second largest biotech IPO of last year. Kingsley Taft co-chairs the firm's life sciences group, and regularly advises life sciences clients in a variety of business and financial affairs. Stuart Cable focuses on transactions and corporate financing, representing several high-profile clients. Maggie Wong advises a variety of innovative public and private life sciences clients in raising capital. She was involved in the noteworthy biotech IPO for BridgeBio.

Notable individuals in the litigation and enforcement area are Joanne Gray and William Harrington, both based in the firm's New York branch. Gray serves as chair of the firm's products liability and mass torts practice group. Harrington, whose practice focuses on government investigations and white-collar matters, has expertise in health care fraud, the Anti-Kickback Statute, False Claims Act and the Stark Act.

A leading practitioner in the regulatory group is Julie Tibbets, who specializes in product development, marketing and FDA issues that arise from transactions. In addition to pharmaceuticals, her technology expertise extends to biologics, medical devices, diagnostics, food, and other areas. Tibbets recently advised Protalix Biotherapeutics in FDA-related matters, and Henry Schein with respect to FDA and FTC matters.

Hogan Lovells

Hogan Lovells is an international firm with a full-service practice in the life sciences area. The firm is notable for its all-encompassing regulatory practice, for which it receives top rankings across the board. The life sciences group also receives national ratings for its practices in general corporate, M&A, licensing and collaboration, venture capital, product liability and white-collar matters.

The firm's top-ranked regulatory practice includes "terrific" partner David Fox, who is highly regarded as an advisor to pharmaceutical companies in FDA clearance. For his stellar career and continued high-profile work in the area, Fox was inducted into the LMG Life Sciences Hall of Fame as part of the 2020 class. Medical device advisor Jonathan Kahan boasts more than 40 years of experience practicing law and is similarly recognized as one of a small group of practitioners in the Hall of Fame. He was recently active for Vayu Global Health Innovations in relation to an Emergency Use Authorization for its bubble CPAP device. In the pricing and reimbursement arena, Alice Valder Curran is widely considered one of the standouts in her field, often advising on matters related to the Medicaid Drug Rebate Program, the Medicare average sales price (ASP) reporting requirement, and the Health Resources and Services Administration (HRSA) drug pricing program. Another standout is Beth Roberts, who earned the 2020 Pricing & Reimbursement Attorney of the Year award for her involvement in a noteworthy National Coverage Determination involving CAR-T therapies.

A peer praises the firm for its "strong regulatory group supporting the transactional practices," and "excellent, deep knowledge of the life sciences industry" as it relates to corporate matters. Adam Golden is head of the corporate group in New York, and represents clients in several high-profile transactions as well as collaboration agreements. Philadelphia-based Steve Abrams represented Optinose, a pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) specialists, with its public offering worth $39 million.

Jonathan Diesenhaus has extensive experience advising a number of life science clients involving criminal investigations and enforcement matters. Nationally renowned attorney Neal Katyal contributes to the firm’s deep appellate capabilities, often in the product liability space. Lauren Colton serves as head of the firm's products law practice group, offering expertise in mass torts and class actions facing life sciences companies.

Latham & Watkins

Latham & Watkins is an international firm with a strong roster of litigators and counselors focused on the life sciences industry. The firm is deeply qualified in the financial space, evidenced by its top ranking in every practice area involving transactional and corporate work. Its litigation department also stands out for its offering in IP, antitrust and white-collar matters. For its wide-ranging activity in the industry, Latham & Watkins was awarded 2020 Life Cycle Firm of the Year by LMG Life Sciences, a recognition earned for the second year in a row.

Judith Hasko is vice chair of Latham's life sciences and healthcare group, and is widely recognized for her work in the licensing and collaboration space. She is a member of the LMG Life Sciences Hall of Fame for her status in the industry. Hasko’s recent representations include Oasmia Pharmaceuticals in its strategic partnership with Elevar Therapeutics, and Ridgeback Biotherapeutics in its collaboration with Merck. Co-chair of the firm’s life sciences and healthcare group is Brian Cuneo was named Venture Capital Attorney of the Year in 2020 for his notable activity in financings. He was recently active for Omniome in its $60 million Series C financing, and Insitro in its $143 million Series B. About Boston-based partner Peter Handrinos, a client says: “He's very good at clearly explaining complex things and reassuring non-lawyers that everything is okay. I like his team and trust the lawyers he chooses. He has a good feel for people.”

IP litigation co-chair Michael Morin receives acclaim from numerous peers in the space, supported by his continued work in high-profile matters related to biologics. He and partner David Frazier recently acted for client AbbVie and Pharmacyclics in two patent infringement suits against AstraZeneca related to its Imbruvica drug. Morin was the 2020 winner of the Patent Litigator of the Year award in DC. Maximilian Grant is a respected litigator who had a major part in the firm’s IP growth. He recently represented InfoBionic in two cases brought by competitor CardioNet. Kenneth Schuler and Daniel Brown acted for Par Pharmaceutical in a Hatch-Waxman dispute in the District of Delaware.

For non-IP litigation, the firm garnered significant awards attention in 2020 for its involvement in a noteworthy litigation involving an HHS rule. The matter, Merck & Co v United States Department of Health and Human Services, was one of the Non-IP Impact Cases of the Year, and involved one of the year’s litigation awardees Daniel Meron. Meron is healthcare and life sciences group co-chair, and a specialist in regulatory enforcement, investigations and other areas of litigation. Global antitrust chair Amanda Reeves and partner Daniel Wall were active for Genentech in an antitrust suit filed in the Southern District of New York by a Russian biotech company, alleging the client engaged in anticompetitive activity.

Latham's regulatory team includes standout attorneys Benneville HaasStuart Kurlander and John Manthei. Manthei serves as global co-chair of the firm's healthcare and life sciences practice group, and is focused on representing clients in all areas of a product's regulatory life cycle. Manthei led the Latham team representing Chinese conglomerate Tencent, advising on FDA requirements and other tariff questions in relation to the company’s donation of personal protective equipment (PPE) to US hospitals as a result of the Covid-19 outbreak. Kurlander heads a Latham team that serves as regulatory and reimbursement counsel to Abbott Diabetes Care.

Morgan Lewis & Bockius

Morgan Lewis & Bockius has an all-encompassing practice in the life sciences space. The firm receives national ranking for its involvement in white-collar matters, licensing and collaboration, patent litigation, regulatory counseling and general corporate work. Recently, the firm made news for its significant streak of lateral hires, particularly in the IP group.

For non-IP litigation, group chair Eric Sitarchuk is one of the firm's senior practitioners focused on white-collar and corporate investigations. He and partner Steven Reed are currently active for Teva and affiliated companies in its defense of numerous claims concerning opioid sales and distribution John Dodds has experience representing pharmaceutical and medical device companies in government investigations, bolstered by his credentials as a former prosecutor in the public sector. Among his current representations, Dodds is active for a drug maker client in an ongoing investigation. Antitrust stars Gordon Cooney and Steven Reed are representing Teva and Glenmark in a multidistrict litigation (MDL) that arose from a Department of Justice investigation involving alleged price fixing practices among generic drug makers.

In the financial and corporate group, global life sciences co-chair Alan Leeds was awarded Licensing & Collaborations Attorney of the Year. One peer notes Leeds is “very good, thoughtful, reasonable, and helps clients in a practical way.” In the past year, Leeds was part of a team representing Regeneron in a collaboration with Vyriad, which develops targeted cancer therapies. Leeds also led a team that advised Celgene in its collaboration agreement with Editas Medicine. Benjamin Pensak is a go-to for life sciences-related licensing agreements and collaborations. He recently advised Eli Lilly in its collaboration with Evox Therapeutics to develop treatments for neurological disorders. David Glazer is “fantastic” notes one peer and worked with Leeds on the Regeneron-Vyriad partnership.

The firm offers a full suite of regulatory services to clients in the industry, with the ability to advise clients at all stages of product development. Kathleen Sanzo has extensive experience assisting a number of high-profile pharmaceutical and biotechnology companies with regulatory and compliance issues. In 2020, she was shortlisted for the FDA Pharmaceutical Attorney of the Year award for her work in the area. Michele Buenafe advises both pharmaceutical and medical device clients in a host of matters, including development, manufacturing, marketing, labeling and advertising issues. Buenafe is the leader of the firm's digital health initiative and co-leader of the firm's cross-practice healthcare initiative.

In IP, the firm drew awards attention for its involvement in of the Patent Impact Cases of the Year: iNo Therapeutics v Praxair Distribution. Life sciences IP group co-head Michael Abernathy was a lead on the matter, which resulted in a Federal Circuit decision involving method of treatment claims that were found invalid under Section 101. In prosecution and strategy, Jeffry Mann is one of the firm's leading practitioners for life sciences patent advice. He specializes in patent preparation and prosecution, IP portfolio monetization, due diligence and licensing. Boston-based Steven Frank focuses his practice on IP transactions, patent prosecution and strategic counseling. LMG Life Sciences newcomers Louis BeardellChristopher Betti and Gargi Talukder also contribute to the firm’s strong patent offering.

Sidley Austin

Sidley Austin's national rankings in nearly all areas of life sciences law positions the firm as one of the premier practices to call on for life cycle management of a product. Areas the firm is highly ranked include product liability, government investigations, patent litigation, pricing, M&A, and licensing, among others.

Litigation partner and "product liability rock star" Debra Pole was one of a few practitioners inducted into the LMG Life Sciences Hall of Fame, highlighting her leading status in the industry. She has been consistently ranked for her practice focused on trials and multidistrict litigation. Co-head of the firm's product liability and mass torts practice Heidi Levine is lauded by peers for her representation of pharmaceutical and medical device clients in large-scale actions. Maja Eaton is another leader in the product liability group, offering deep expertise in mass torts and class actions. Paul Kalb plays multiple leading roles at the firm, including his positions as global head of the healthcare and FDA practice, and life sciences industry group co-chair. Kristin Koehler is an active practitioner in the firm’s government investigations group, who recently acted for a major pharmaceutical client in a qui tam matter related to government contracts.

In IP, the firm received significant awards attention in 2020, winning multiple practitioner categories and a Patent Impact Case of the Year award for its involvement in the high-profile appeal Immunex v Sandoz. One of the firm’s IP litigation heads is Jim Badke, who is currently active for Bayer Healthcare in a biologics litigation against Baxalta and Nektar involving the client’s Jivi product. Ching-Lee Fukuda is the 2020 Post-Grant Proceedings Attorney of the Year for her significant activity in PTAB matters, including the recent appeal of an IPR for client Nevro invalidating a key Boston Scientific patent. She was also active in a Patent Impact Case of the Year CardioNet v InfoBionic, which reversed a ruling citing Section 101. The firm was also recognized for its appellate win in Immunex v Sandoz appeal, which dealt with obviousness-type double patenting.

For regulatory matters, the firm draws on a deep bench of experienced attorneys to assist clients in all areas of product development and pricing matters. Coleen Klasmeier is former head of the firm's food, drug and medical device regulatory practice and a member of the firm's executive committee. She focuses her practice on representation of life sciences companies in contentious proceedings involving the FDA. Another standout in the regulatory group is Raj Pai, who focuses his practice on clients in the pharmaceutical and biotechnology sectors. He has previously represented companies in government investigations, enforcement proceedings, and litigation.

The financial and corporate group leverages its global team to assist clients with public offerings, transactions, licensing, collaborations, and venture capital financing. West Coast-based Joshua Hofheimer represented Yuhan Corporation in its licensing and collaboration agreements with Gilead and Janssen, a division of Johnson & Johnson. Pran Jha is experienced in public offerings, transactions, and collaborations. He recently represented clients CSL Behring and Vifor Pharma in notable deals. Bay Area-based partners Jennifer Fitchen and Sharon Flanagan add to the firm’s West Coast credentials. Fitchen is global co-leader of the firm's mergers and acquisitions practice.

WilmerHale

WilmerHale is recognized as a leading firm in the life sciences sector for its multifaceted practice assisting companies in pre- to post-market matters. The firm is graded highly in a number of legal disciplines, including patent litigation, white-collar matters, licensing and collaboration, and general corporate work.

New York partner Robert Gunther is a key member of the firm’s life sciences patent litigation bench, and was honored in 2020 as the General Patent Litigator of the Year in New York for his significant activity in the area. Among his notable representations was a consolidated case for Roche and Becton Dickinson against Enzo Life Sciences, which resulted in a noteworthy Federal Circuit ruling involving enablement issues. The matter was named one of 2020’s Patent Impact Cases of the Year. IP litigation group co-chair Lisa Pirozzolo is an experienced first-chair trial lawyer who is representing several notable life sciences clients, including CSL Behring in a dispute against Biogen related to hemophilia treatment. William Lee is one of the most celebrated patent litigators in the country, offering more than four decades of experience in law. DC-based partner Amy Wigmore is currently active for Bristol-Myers Squibb and Pfizer in a Hatch-Waxman litigation opposite several generic manufacturers that at one point totaled 25 challengers.

The firm's corporate capabilities are supported by several experienced attorneys, including Steven Barrett, who co-chairs the technology transactions and licensing practice group. He recently represented Ribometrix in a collaboration with Vertex Pharmaceuticals, and Medtronic in funding agreements with Blackstone Life Sciences. Transactional department chair Lia Der Marderosian represented Pandion Theraupetics, a biotechnology company focused on autoimmune diseases, in its $80 million Series B financing. Life sciences group co-chair Stuart Falber advises a variety of life sciences clients ranging from startups to established companies in the space. He specializes in corporate and venture capital transactions, as well as licensing and collaboration agreements. Among his notable matters, Fabler advised Epizyme in its $270 million collaboration agreement with Royalty Pharma. Steven Singer has over 30 years of experience assisting both public and private life sciences companies in various transactions. A new addition to this year’s list is Cynthia Mazareas, who represents both a number of high-profile private and public life sciences companies with a variety of issued related to corporate governance and transactions.

In the enforcement area, the firm is noteworthy for its practice focused on government investigations and white-collar matters. Securities litigation practice co-chair Michael Bongiorno recently took part in an appellate matter for Ocular Therapeutix and its former officers, resulting in a First Circuit ruling that the clients did not mislead investors regarding manufacturing and regulatory aspects of drug candidate Dextenza. Howard Shapiro is chair of the firm's litigation and controversy department, with more than three decades of experience handling disputes, particularly in the area of white-collar defense.

Non-IP Litigation & Enforcement
Arnold & Porter

Arnold & Porter is a full-service life sciences firm with top-tier status in antitrust and product liability matters, with an additional national ranking in white-collar defense. A peer notes the firm has \solid credentials\" in life sciences-related litigation. For the firm's involvement in high-profile competition suits, Arnold & Porter was awarded 2020 Antitrust Firm of the Year by LMG Life Sciences, the second year in a row the firm earned the honor."

Bradley Arant Boult Cummings

Headquartered in Birmingham with additional offices across the southeast, Bradley Arant Boult Cummings is a full-service law firm with a growing national reputation. The firm offers litigation services to a variety of clients in the life sciences industry, with a particular emphasis on product liability cases.

Leading the firm's representation of companies in the industry is Lindsey Boney, who has been involved in several high-profile cases involving major pharmaceutical clients. Boney served as lead counsel for Bayer in a number of lawsuits involving the drug Xarelto, leading the strategy and legal briefing team. Kim Martin is another star who worked alongside Boney in the Bayer case, leading the discovery team. Martin and Boney are also active for Pfizer as national counsel in a set of litigations claims of injury connected to use of the client’s anti-arrhythmic drug Cordarone.

Tripp Haston is based in the firm's office in Birmingham and is highly regarded for his defense of pharmaceutical giant Pfizer in numerous matters. In addition to his active practice in the products space, Haston was also recently active for Hospira in a commercial arbitration, and PRA Health Sciences in a breach of contract suit. He is also active as a lead partner on the Xarelto and Cordarone product liability matters. Haston was shortlisted for the Product Liability Attorney of the Year award in 2020 for his activity in the area.

Additional standout practitioners in the firm’s life sciences litigation group are Lela Hollabaugh, David Hymer and Dana Lumsden.

 

Debevoise & Plimpton

Long considered one of New York's premier law firms, Debevoise & Plimpton continues to grow its profile in life sciences with a standout bench of litigators. The firm is notable for its practices focused on white-collar defense and antitrust matters, supported by a team of attorneys staffed in its New York base and Washington, DC branch.

In the white-collar and government investigations space, New York partner Mark Goodman is a notable presence, particularly for his specialty as counsel to boards of directors. Goodman serves as co-chair of the firm's commercial litigation group, and is a senior member of its white-collar and regulatory defense group. He was recently active for a life sciences client counseling the company on compliance matters.

DC-based Ted Hassi is a noteworthy practitioner in the firm's litigation department, and is widely considered a top antitrust litigator. He leverages his background as former Chief Trial Counsel for the FTC in his practice representing clients against anticompetitive claims.

Dechert

Headquartered in Philadelphia with several domestic and international offices, Dechert is routinely recognized for its strong group of life sciences attorneys across practice areas, including product liability and antitrust litigation. The firm notably boosted its products law profile with the recent hiring of a Quinn Emanuel Urquhart & Sullivan team dedicated to this area.

Based in New York, Sheila Birnbaum is co-chair of the firm's product liability and mass torts practice. Birnbaum, who was part of the move from Quinn Emanuel in 2018, is considered "The Queen of Torts," by a peer. Fellow co-chair Mark Cheffo is highly regarded for his work in high-stakes litigation and is the 2020 Product Liability Attorney of the Year for his significant activity in the area. Cheffo’s notable case work from the past year includes representing Purdue in matters related to opioid products, and Pfizer in a matter the invoked preemption issues.

In Chicago, Nathan Hoffman is currently representing AbbVie in national product liability litigation related to the client's product AndroGel, a testosterone replacement therapy. The Dechert team developed and defended the company witnesses through both deposition and trial, and responded to all written and documentary discovery aimed at the company. Currently the firm is active as settlement counsel for AbbVie in the matters.

For antitrust matters, George Gordon is one of the firm’s experienced practitioners. He is currently representing Endo in defense of several class actions involving “reverse payment” claims connected to its Opana ER product.

Gibson Dunn & Crutcher

International firm Gibson Dunn & Crutcher earns top-tier status in the antitrust and white-collar areas, with an additional recognition for product liability.

Based in the firm’s Orange County office, Jeffrey Thomas has dual expertise in litigation related to antitrust and intellectual property. He recently represented Amgen in an antitrust litigation filed by Cipla, derived from a settlement of a patent infringement dispute between the client and Teva. The matter is currently pending.

San Francisco partner Winston Chan supports the firm's reputation as a go-to firm for government investigations. He has deep experience in matters related to the False Claims Act, Foreign Corrupt Practices Act and Anti-Kickback Statute. Reed Brodsky is co-chair of the firm’s crisis management practice group and a member of the government investigations department. He is a trial lawyer well-versed in matters related to securities, compliance counseling, internal investigations and commercial disputes.

Goldman Ismail Tomaselli Brennan & Baum

Goldman Ismail Tomaselli Brennan & Baum is a destination for product liability and antitrust matters, exemplified by its top national ranking in those areas by LMG Life Sciences. One competitor describes the firm as “the group brought in as firepower for trial counsel,” while another simply labels it: “Small outfit, high quality.” For the firm’s continued status as a stalwart in life sciences class actions and MDLs, and recent work for major clients AbbVie, Bayer and Johnson & Johnson, Goldman Ismail was awarded 2020 Product Liability Firm of the Year by LMG Life Sciences.

Much of the firm's reputation in product liability is founded on the practices of name partners Kenneth BaumAndrew GoldmanTarek Ismail and Joe Tomaselli, who have significant experience handling matters for life sciences companies. Baum and partner Shayna Cook are currently active as national counsel for Bayer Healthcare in pending litigation involving the client’s contraceptive product Mirena. The team recently obtained summary judgment for Bayer through the MDL court citing lack of evidence from the plaintiffs. For her work in this and other recent matters, Cook was shortlisted for the 2020 Product Liability Attorney of the Year award by LMG Life Sciences.

A team including Tarek Ismail, Shayna Cook, Joe Tomaselli and Andrew Goldman represented Johnson & Johnson entity Ethicon as trial counsel in a product liability litigation involving transvaginal mesh. In early 2020, the team achieved a full defense verdict in favor of Ethicon after a two-week trial.

In the antitrust area, the firm is active for Merck as strategic defense counsel in multiple putative antitrust class actions alleging reverse payment settlement claims related to a Hatch-Waxman suit.

Hogan Lovells

DC-based Hogan Lovells is a global, full-service law firm that is widely considered a juggernaut in the life sciences industry, offering specialized practices focused on antitrust, white-collar defense and regulatory enforcement. The group was shortlisted for the Government Investigations Firm of the Year award in 2020 for significant activity in False Claims Act cases and other matters.

Denver-based Michael Theis leads the firm’s False Claims Act practice group, leveraging his experience as a former trial attorney with Department of Justice to assist clients with investigations and white-collar matters. For his work in the area, Theis was recently shortlisted for the Government Investigations Attorney of the Year award. Jonathan Diesenhaus has extensive experience advising life science clients in criminal investigations and enforcement matters. His practice often involves qui tam matters brought by whistleblowers or government entities. Virginia Gibson is a well-respected trial lawyer who has defended clients from Anti-Kickback Statute claims and other matters related to the False Claims Act. Gibson has a background as a federal prosecutor.

Lauren Colton heads the firm’s product liability group, contributing to the firm’s deep expertise in mass torts and class actions. She is currently acting for Bristol-Myers Squibb as national coordinating counsel in a multidistrict litigation related to the client’s Abilify drug. Recently involved in the product liability space is Neal Katyal, who has earned his status as a leading appellate litigator with a strong track record in life sciences disputes. He recently represented Bristol-Myers Squibb (BMS) and Pfizer in a multi-district litigation, resulting in a Second Circuit ruling that ended the matter in favor of the clients. Prior to his private practice at Hogan Lovells, Katyal served as Solicitor General of the United States.

King & Spalding

With origins in Atlanta, King & Spalding is today a global powerhouse with a dominant position in many areas of practice. In the life sciences arena, the firm offers noteworthy practices in product liability and government investigations, areas the firm retains top-ranking nationally. For the firm’s significant activity in white-collar defense matters, King & Spalding was awarded Government Investigations Firm of the Year in 2020 by LMG Life Sciences.

DC's Wick Sollers contributes to the firm’s deep bench strength in the white-collar defense arena, steering King & Spalding’s practice as leader of the government matters team. He is currently active for a major pharmaceutical client in an investigation. Mark Jensen is another standout in the government investigations practice who recently acted alongside Sollers in the pharmaceutical matter. John Richter is former Acting Assistant Attorney General for the Criminal Division at the DOJ, drawing on his significant government expertise to represent clients in white-collar and regulatory matters. He was recently active for a medical device company in an anti-bribery investigation. The firm’s group was also recently boosted with the addition of former US Deputy Attorney General Sally Yates, whose practice focuses on investigations and compliance matters.

Houston's Tracie Renfroe is currently representing Janssen, Johnson & Johnson and related subsidiaries as national coordinating counsel in a putative class action alleging the clients’ Elmiron drug can cause permanent vision damage. Los Angeles's Alexander Calfo secured a defense verdict for Johnson & Johnson in a lawsuit alleging the client’s talcum powder product caused asbestos contamination. Following a three-week trial, a jury rejected the plaintiff’s claims and found he had not been exposed to asbestos through the powder. The firm also serves as national coordinating counsel in further talc cases.

Latham & Watkins

Latham & Watkins offers a substantial footprint in the litigation space, earning top marks for its practice focused on antitrust litigation and recommended status in the government investigations space. The firm garnered significant awards attention in 2020 for its involvement in a noteworthy litigation involving a Department of Health and Human Services rule.

Antitrust veteran Daniel Wall and LMG Life Sciences newcomer Amanda Reeves were active for Genentech in an antitrust suit filed in the Southern District of New York by a Russian biotech company, alleging the client engaged in anticompetitive activity. Reeves, who currently serves as chair of the firm’s global antitrust practice, is also active in antitrust transactions in addition to litigation.

Healthcare and life sciences group co-chair Daniel Meron is a specialist in regulatory enforcement, investigations and other areas of litigation. Among his notable matters from the past year, Meron was involved in one of the Non-IP Litigation Impact Cases of the Year for clients Amgen, Eli Lilly and Merck that invalidated an HHS rule requiring drug prices to be shown in pharmaceuticals advertisements. Meron was awarded Government Investigations Attorney of the Year in 2020 for his work in the area.

Mayer Brown

Headquartered in Chicago with an additional 25 offices worldwide, Mayer Brown is an international, full-service law firm with a significant presence in the life sciences space. In particular, the firm is noted for its robust antitrust and product liability practices.

Daniel Ring acted for Medtronic before the Minnesota Court of Appeals in this noteworthy product liability case dealing with preemption following the landmark Merck v Albrecht ruling. Ring is co-chair of the product liability and mass torts group.

New York partner Hank Bullock supports the firm’s strong offering in product liability, recently acting for GlaxoSmithKline in more than 10 actions stemming from claims brought against the client’s Lamictal product. The firm is active as counsel for the discovery, trial and appellate stages of the case.

McDermott Will & Emery

McDermott Will & Emery is an international law firm with a reputable group of attorneys specialized in non-IP litigation services for a variety of life sciences clients. DC-based Ray Jacobsen is global head of the firm's antitrust practice, with over 30 years of experience representing healthcare and biotechnology companies. He recently assisted Rochester General Health System and Unity Health System in securing FTC approval for the merger of hospitals in Rochester, New York.

Morgan Lewis & Bockius

Morgan Lewis & Bockius's national rankings in government investigations and antitrust are supported by an experienced team of litigators with a deep focus on life sciences clients. The firm had a new addition to the LMG Life Sciences stars list with Ethel Johnson, who made headlines with a recent product liability verdict that reduced an $8 billion judgment against client Johnson & Johnson to $6.8 million. Johnson was shortlisted in the Non-IP Trial Lawyer of the Year category for her work in the area.

Eric Sitarchuk is a senior partner in the Philadelphia office and current chair of the firm's white-collar and corporate investigations practice. He is experienced in a diverse set of matters, including cases that involve the False Claims Act, Foreign Corrupt Practices Act and qui tam claims. He and partner Steven Reed are currently active for Teva and affiliated companies in its defense of numerous claims concerning opioid sales and distribution. In his antitrust practice, Reed was also active for Vyera and Phoenixus in a lawsuit filed by the FTC claiming two of the company’s former officers violoated antitrust laws with respect to generic competition. John Dodds has experience representing pharmaceutical and medical device companies in government investigations, bolstered by his credentials as a former prosecutor in the public sector. Among his current representations, Dodds is active for a drug maker client in an ongoing investigation.

Gordon Cooney and Steven Reed are representing Teva and Glenmark in a multidistrict litigation (MDL) that arose from a Department of Justice investigation involving alleged price fixing practices among generic drug makers, and is one of the largest MDLs to date. Howard Young is co-head of the firm's healthcare industry initiative and one of the group's experts on regulatory enforcement and investigations. He and partner Scott Memmott are currently representing device maker Joerns Healthcare in a civil False Claims Act litigation.

O'Melveny & Myers

In the life sciences area, O’Melveny & Myers continues to be significantly active in the product liability and class actions area, demonstrated by a year of notable trial work for top pharmaceutical and device manufacturers. Product liability and mass torts chair Steve Brody in part supports the firm’s reputation in the area, and recently garnered awards attention from LMG Life Sciences as a finalist for the Non-IP Trial Lawyer of the Year honor for 2020. Among his notable matters from the past year, Brody represented Johnson & Johnson and Janssen Pharmaceuticals in the first opioid products case in the United States to go to trial. The Oklahoma court ordered the client to pay 2.6% of the $17.7 billion claim, and the matter is now on appeal. Brody is also active as lead for Ethicon in multi-state Attorney General investigations related to pelvic mesh products. One of the related cases on appeal in California may raise novel arguments connected to First Amendment, due process and excessive fines issues.

Leading trial lawyers Daniel Petrocelli and Richard Goetz act alongside Brody and the O’Melveny team further assisting Johnson & Johnson in opioid matters, including a multidistrict litigation in Ohio and others cases throughout the country.

Reed Smith

Reed Smith has a longstanding reputation in the product liability space, supported by the firm's national ranking in the area. The firm employs several notable practitioners in this area, echoed by a peer who says: "Reed Smith has product liability litigators all over the place… and among them, there are some real standouts."

Among the firm's senior trial lawyers in the products group is Barbara Binis, who specializes in mass torts, multidistrict litigation and class action defense for life sciences companies and providers. Binis and her team are responsible for overall defense strategy, lead trial counsel roles, and overall coordination in a mass tort litigation brought against clients Endo and its subsidiary AMS. The action, which involves 11 surgical mesh products that treat pelvic organ prolapse and stress urinary incontinence, is one of the largest mass torts to date. Michael K Brown is acting for Becton Dickinson entities CR Bard and Davol in a multidistrict litigation involving hernia mesh products. In two of the cases, Brown and his team secured summary judgment rulings in favor of the clients.

Ropes & Gray

Headquartered in Boston with key offices in New York and Washington DC, Ropes & Gray is a firm of national repute for its litigation expertise. The firm earns top marks in the white-collar and government investigations area, as well as a recommended ranking for its work in antitrust matters. About the litigation group, a peer says Ropes & Gray offers an "excellent team."

Brien O'Connor is a leading practitioner for white-collar defense and government investigations, who a peer labels a "very thoughtful" and "strategic" lawyer. O'Connor specializes in False Claims Act cases, healthcare fraud disputes, internal investigations and compliance, among other areas. He is currently active for a pharmaceutical client in a nationwide dispute. Joshua Levy is co-chair of the firm's global litigation and enforcement group, with a practice focused on white-collar defense and civil litigation. He is currently representing a life sciences company and its Board of Directors in multiple matters. Additional standouts in the white-collar defense group are DC-based Colleen Conry and New York's Joan McPhee.

Head of the antitrust practice group is Mark Popofsky, who has significant experience representing clients in the technology sector, including pharmaceutical, biotech and medical device companies. He is currently defending a biotech client against claims of anticompetitive practices.

Sidley Austin

With origins in Chicago and still one of that city's mainstay entities, Sidley Austin has since grown to a dominant position on the national stage, with star players populating all of its offices throughout the US. "I can't think of any firm off the top of my head that even comes close," ventures a peer. "From regulatory clearance, to IP, and right down to all-out court battles, Sidley has got it all covered. They really do it all." Another peer says, "Sidley is a great healthcare litigation firm." The firm maintains top rankings nationally for product liability and white-collar defense, with an additional mention for its team focused on antitrust matters.

Co-head of the firm's product liability and mass torts practice Heidi Levine is lauded by peers for her representation of pharmaceutical and medical device clients in large-scale actions. "Product liability rock star" Debra Pole represented Janssen Pharmaceuticals before a Philadelphia court, winning a key mid-trial victory when a Pennsylvania state judge issued a decision denying claims that an adolescent boy grew female breasts after being prescribed the antipsychotic drug Risperdal. Another product liability star is Maja Eaton, who recently represented Ferring Pharmaceuticals in class-action litigation, as well as individual personal injury and economic loss lawsuits, that have arisen out of the company's recall of fertility drug Bravelle.

Paul Kalb plays multiple leading roles at the firm, including his positions as global head of the healthcare and FDA practice, and life sciences industry group co-chair. In his individual practice, Kalb focuses on regulatory enforcement involving the FDA, and white-collar defense as it relates to fraud and abuse claims and off-label promotion. Additional standouts in the government investigations practice are DC-based partners Mark Hopson and Kristin Koehler.

Skadden Arps Slate Meagher & Flom

International law firm Skadden Arps Slate Meagher & Flom is noted by peers as having a “first-tier” life sciences mergers and acquisitions practice. The firm, which was recognized as the 2020 M&A Firm of the Year, is highly regarded for representing a number of high profile pharmaceutical and medical device companies, as well as emerging life sciences entities.

Graham Robinson is head of the firm’s Boston mergers and acquisitions group and is noted for representing both public and private companies in a number of transactions. Among his recent matters, Robinson, who one peer describes as a “great lawyer,” led the Skadden team advising Array BioPharma in its $11.4 billion acquisition by Pfizer, as well as Gilead Sciences in its $5.1 billion transaction with Galapagos NV.

In New York, the firm has perennial stars Marie Gibson and Paul Schnell. Gibson recently represented Foamix Pharmaceuticals in its merger with Menlo Therapeutics while Schnell was part of a team that advised Pfizer in two separate notes offerings which totaled $5.25 billion.

Venable

Headquartered in Baltimore with an additional seven offices across the country, Venable is a full-service law firm with a significant presence in the life sciences space. In particular, the firm offers a host of litigation services to clients in the industry, including representation in product liability suits and government investigations.

Stephen Marshall is a seasoned litigator who is highly regarded for his expertise in product liability matters. Most notably, Marshall is leading a team that serves as national counsel for Merck in a case involving one of the company's products, Fosamax. In addition, Marshall represents Merck in separate litigation related to its prescription drugs Propecia and Proscar.

Working alongside Marshall in Baltimore on a number of matters is litigation standout Craig Thompson and new star Bruce Parker. Thompson and Parker currently lead the team serving as co-national counsel for Takeda in litigation involving the company's proton-pump inhibitor (PPI) medications, including Prevacid and Dexilant, which plaintiffs allege caused kidney injuries.

Williams & Connolly

As a purely litigation-based shop, Washington DC's Williams & Connolly is routinely engaged on the front lines of virtually any litigation matter. A recent client praised the firm’s work on a litigation, saying: “Williams & Connolly's work on this matter has been exceptionally excellent in all areas, [including] strategy, brief writing, oral advocacy, and client relations, to name a few.” While the firm's individual and collective trial prowess extends well beyond the life sciences industry, Williams & Connolly has seen some particularly noteworthy successes in this arena.

In the product liability capacity, widely championed trial lawyers Heidi Hubbard and Joseph Petrosinelli continue to garner nearly unanimous plaudits from their peers in the pharmaceutical and medical device arena. Hubbard was recently active as appellate and legal strategy counsel for GlaxoSmithKline in connection with pending claims made against the client’s Zofran product. The firm also got a significant augmentation in the appellate capacity when Lisa Blatt rejoined the firm after the lengthy stint at Arnold & Porter. "Lisa Blatt really has a 'hot hand' in those appeals for pharma industry players," observes a peer. Enu Mainigi, a noted white-collar and enforcement and antitrust partner, has doubled down on her dedication to the life sciences field through her representation of Cardinal Health in the massive and unprecedented opioid litigation. She was shortlisted in two areas for the 2020 LMG Life Sciences Awards, including Government Investigations Attorney of the Year and Non-IP Trial Lawyer of the Year.

Regulatory
Arnold & Porter

Headquartered in DC, Arnold & Porter is a full-service firm with an established reputation for assisting a wide range of life science clients with regulatory issues. In addition to handling all matters for pharmaceutical and medical device companies in front of the FDA, the firm also has experienced professionals in the pricing and reimbursement space.

Covington & Burling

Covington & Burling is an international, full-service firm with a deep bench of attorneys focused on life sciences clients. The firm handles a variety of regulatory matters, earning national rankings in the FDA area for both pharmaceuticals and medical devices.

Michael Labson advises a number of pharmaceutical and biotechnology companies with FDA-related issues and his highlighted by one peer as a “really strong lawyer.” Among his recent work, Labson served as lead counsel for Genentech in a FDA hearing and testified on behalf of the Pharmaceutical Research and Manufacturers of America (PhRMA) in front of Congress. This year he was shortlisted by LMG Life Sciences for the top attorney award in the FDA Pharmaceutical area.

Geoffrey Hobart focuses his practice on defending a variety of clients in FDA investigations, which can involve issues related to the False Claims Act, Anti-Kickback Act, as well as Medicaid Rebate statute violations.

With over 20 years of experience, Pamela Forrest handles a number of FDA medical device matters. Forrest advises clients throughout the entire life cycle including pre-market notification and approval, product recalls, and device labeling and promotion.

Hogan Lovells

Co-headquartered in London and Washington DC, Hogan Lovells is consistently ranked for having one of the premier life sciences regulatory practices and is this year’s LMG Life Sciences Regulatory Firm of the Year. One client describes the firm as being "top-notch," with a group of attorneys who possess "a very deep knowledge of the law." The firm's depth gives it the ability to assist a variety of life sciences clients in all aspects of the regulatory process.

David Fox is highly regarded for assisting a number of pharmaceutical companies with their regulatory issues. One peer comments that Fox is "terrific," while another describes him as an "absolute star" in the field. Among his recent matters, Fox served as lead partner representing Intra-Cellular Therapies through the FDA approval process for the company’s Caplyta program, a treatment for schizophrenia.

Operating from both the firm's Washington, DC and Denver offices, Meredith Manning has over 20 years of experience counseling a variety of pharmaceutical clients in regulatory matters. One clients exclaims that Manning and her team "are extremely competent and knowledgeable on FDA regulatory matters" and are "responsive, thorough and able to explain complex rules in an understandable way."

Jonathan Kahan is a "star" according to one peer, and has over 40 years of experience assisting medical device and diagnostics companies with their regulatory issues. He was recently active for Vayu Global Health Innovations in relation to an Emergency Use Authorization for its bubble CPAP device.

In the pricing and reimbursement arena, Alice Valder Curran is widely considered one of the standouts in her field with one peer noting she has “great respect” for her work. She regularly advises clients on matters related to the Medicaid Drug Rebate Program, the Medicare average sales price (ASP) reporting requirement, and the Health Resources and Services Administration (HRSA) drug pricing program. Valder Curran currently serves as chair of the firm's global regulatory practice.

Beth Roberts is this year’s LMG Life Sciences Healthcare Pricing & Reimbursement Attorney of the year and is noted for representing a number of high-profile life sciences clients. One peer notes Roberts is “fantastic” to work with while another peer highlights she “top notch” in the field. Roberts served as lead regulatory counsel for Celgene in a noteworthy NCA matter related to CAR-T therapy.

Hyman Phelps & McNamara

Hyman Phelps & McNamara is a boutique law firm that solely focuses on regulatory matters. The firm assists a variety of pharmaceutical and medical device companies with their regulatory issues. As a boutique, Hyman Phelps provides clients with FDA expertise throughout all stages of product development, including pre-market approvals and compliance, to post-market labeling, advertising and promotion. One peer notes the firm is an “absolute juggernaut” in the space.

Jeffrey Gibbs offers his extensive experience handling FDA regulatory issues on behalf of clients in the life sciences industry. His active practice primarily involves counseling medical device companies. Gibbs assists with regulatory strategy, 510(k) clearances, approvals, and post-market regulation advice and guidance.

On the pharmaceutical side, Josephine Torrente assists companies at every stage of product development, from pretrial counseling to post-market representation in front of the FDA. Torrente advises clients on a variety of drug development issues, specifically focusing on serious and life-threating diseases.

Jeffrey Shapiro is highly regarded for his work representing clients in the medical device area. Shapiro has over 20 years of experience assisting clients before the FDA and is considered an expert in the regulation of combination products. "Jeff Shapiro and his team have done a fantastic job for us in many circumstances, including high-pressure situations with short deadlines," a medical device client says.

King & Spalding

Employing a number of dedicated, DC-based attorneys, King & Spalding offers a strong regulatory practice serving life sciences companies across technology areas. The firm assists both established and emerging clients in the space throughout the entire regulatory life cycle.

Mark Brown is chair of the firm's FDA and life sciences practice and regularly handles a variety of complex FDA compliance matters. Among his recent cases, Brown serves as lead regulatory counsel for a global surgical implant company, advising on a variety of FDA compliance issues.

Co-chair of the life sciences and healthcare industry group Nikki Reeves is experienced in handling both pre- and post-market FDA compliance issues for a variety of pharmaceutical and medical device companies. Reeves currently counsels Amryt Pharmaceuticals with its implementation of various enforcement agreements.

John Shakow assists a number of pharmaceutical and biotechnology companies with pricing and reimbursement matters. Shakow is currently leading a team representing Ipsen Biopharmaceuticals in a lawsuit against the Department of Health and Human Services.

A new addition to this year’s list is Seth Lundy and serves as deputy chair of the firm’s FDA and Life Sciences practice group. Lundy is highly regarded for assisting both pharmaceutical and medical device companies with regulatory issues. Recently, he was part of the leadership team that advised Henry Schein, a major medical product distributor, with regulatory concerns regarding distributions of Covid-19- related diagnostics tests and personal protection equipment (PPE) to healthcare institutions.

Latham & Watkins

International law firm Latham & Watkins has an emerging regulatory practice led by perennial LMG Life Sciences star John Manthei. Manthei, who also serves of global chair of the firm’s healthcare and life sciences group, focuses his practice on assisting a variety of pharmaceutical and medical device companies with matters involving the FDA. Among his recent clients, Manthei led the Latham team representing Chinese conglomerate Tencent, advising on FDA requirements and other tariff questions in relation to the company’s donation of personal protective equipment (PPE) to US hospitals as a result of the Covid-19 outbreak.

Another star practitioner at the firm assisting in FDA matters is J Benneville Haas.  In addition to advising a variety of life sciences companies with regulatory issues, Haas also assists in the transactional space, conducting regulatory due diligence for major public offerings, mergers, and other finance-related activities.

Stuart Kurlander focuses his practice on healthcare pricing and reimbursement matters, advising a number of innovative medical device companies. Among his current clients, Kurlander heads the Latham team that serves regulatory and reimbursement counsel to Abbott Diabetes Care (ADC), which manufacturer of diabetes-related medical products. Kurlander assisted ADC in developing a strategy to increase patient access to the company’s continuous glucose monitoring (CGM) device during the Covid-19 outbreak.

McDermott Will & Emery

Noted by a peer for its quality, McDermott Will & Emery represents a wide variety of life sciences companies across regulatory practice areas. The firm has a highly regarded group of attorneys with extensive experience handling cases involving the FDA and other agencies.

Vernessa Pollard counsels a number of medical device companies in regulatory compliance and enforcement. In addition, she also advises financial firms and investors with regulatory issues arising from mergers and other transactional activity. In recognition for her work, Pollard was awarded this year’s FDA Medical Device Attorney of the Year by LMG Life Sciences.

In pricing and reimbursement matters, Paul Radensky is highly regarded for assisting life sciences companies and healthcare institutions. Furthermore, Radensky serves as principal at the firm's healthcare consulting group, McDermott+Consulting.

Morgan Lewis & Bockius

Morgan Lewis & Bockius is an international law firm with a broad-based life sciences regulatory practice. The firm offers a full suite of regulatory services to clients in the industry, with the ability to advise clients at all stages of product development.

Kathleen Sanzo has extensive experience assisting a number of high-profile pharmaceutical and biotechnology companies with regulatory and compliance issues. Life sciences industry group founder Stephen Paul Mahinka brings over 40 years of experience counseling clients in regulatory, compliance and antitrust issues. In addition to his practice, Mahinka often authors articles and books on FDA-related issues.

Michele Buenafe advises both pharmaceutical and medical device clients in a host of matters, including development, manufacturing, marketing, labeling and advertising issues. Buenafe is the leader of the firm's digital health initiative and co-leader of the firm's cross-practice healthcare initiative.

Reed Smith

Headquartered in Pittsburgh, Reed Smith is an international firm with a strong group of DC-based attorneys focused on healthcare pricing and reimbursement matters. Scot Hasselman serves as co-chair of the firm’s life sciences health industry group and is highly regarded for assisting clients with issues related to compliance and fraud counselling, including False Claims Act and federal Anti-Kickback Statute defense.

Another star practitioner at the firm is Carol Loepere, who represents a variety of life sciences companies in healthcare & reimbursement matters. Among her recent clients, Loepere successfully represented a major healthcare provider in a billion-dollar False Claims Act dispute, with the Department of Justice dismissing the case. Other regulatory attorneys at the firm include Robert Hill and Joseph Metro.

Ropes & Gray

Headquartered in Boston with additional domestic and international offices, Ropes & Gray has a robust life sciences practice adept at handling a number of regulatory issues. The firm is particularly noted for its representation of pharmaceutical and biotechnology clients throughout product life cycles.

Gregory Levine is chair of the firm's regulatory practice group and is highly regarded for advising a variety of clients with FDA-related matters. One peer notes Levine has a “very strong medical device practice and is also strong on the pharma side.” Among his recent clients, Levine is currently part of the Ropes team representing Pfizer with a number of FDA regulatory matters.

Working alongside Levine is Albert Cacozza, who also handles a host of regulatory matters, with a particular emphasis on product compliance, advertising and promotion. Cacozza recently advised Blackstone Life Sciences on the regulatory considerations regarding its $2 billion collaboration agreement with Alnylam.

Kellie Combs is a new addition to this year’s list and was previously recognized as a rising star in the regulatory space by LMG Life Sciences. One peer notes Combs is “not just very good, she is excellent.” Combs is recognized for assisting a variety of pharmaceutical and medical device companies, with a particular expertise in the digital health arena, serving as co-chair of the firm’s Digital Health Initiative. Tom Bulleit is another addition to the stars list, who leads the regulatory matters for Pfizer related to state pricing policies.

Sidley Austin

Sidley Austin is an international, full-service law firm with a comprehensive life sciences regulatory practice. The firm draws on a deep bench of highly experienced attorneys to assist clients in all areas of product development and pricing and reimbursement matters.

Coleen Klasmeier is former head of the firm's food, drug and medical device regulatory practice and a member of the firm's executive committee. Klasmeier, who worked at the FDA Office of the Chief Counsel prior to joining the firm, focuses her practice on representing life sciences clients in contentious proceedings involving the FDA.

Another standout in the regulatory group is Raj Pai, who focuses his practice on clients in the pharmaceutical and biotechnology sectors. He has previously represented companies in government investigations, enforcement proceedings, and litigation. Pai also worked at the FDA prior to joining the firm, and was appointed Special Assistant US Attorney during his time with the agency.

Meenakshi Datta is a new addition to this year’s stars list and is global co-leader of the firm’s healthcare practice. Datta is highly regarded for assisting both large Fortune 100 life sciences companies and emerging firms. Outside her practice, Datta is regularly quoted on regulatory and other healthcare-related topics.